# EDGAR Filing Document

**Accession Number:** 0000084129
**File Stem:** 0001558370-23-000026
**Filing Date:** 2023-1
**Character Count:** 277545
**Document Hash:** 43f6a72c22dd05d620f9338c1eb90b54
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-000026.hdr.sgml**: 20230104

**ACCESSION NUMBER**: 0001558370-23-000026

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 94

**CONFORMED PERIOD OF REPORT**: 20221126

**FILED AS OF DATE**: 20230104

**DATE AS OF CHANGE**: 20230104

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RITE AID CORP
- **CENTRAL INDEX KEY:** 0000084129
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **IRS NUMBER:** 231614034
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0304

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05742
- **FILM NUMBER:** 23504984

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 INTREPID AVENUE, 2ND FLOOR
- **CITY:** PHILADELPHIA
- **STATE:** PA
- **ZIP:** 19112
- **BUSINESS PHONE:** 7177612633

**MAIL ADDRESS:**
- **STREET 1:** PO BOX 3165
- **CITY:** HARRISBURG
- **STATE:** PA
- **ZIP:** 17105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RACK RITE DISTRIBUTORS
- **DATE OF NAME CHANGE:** 19680510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEHRMAN LOUIS & CO
- **DATE OF NAME CHANGE:** 19680510

?xml version='1.0' encoding='UTF-8'?

[**Table of Contents**](#TOC)

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

### FORM 10-Q

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;**☒&nbsp;&nbsp;&nbsp;&nbsp;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| **For the quarterly period ended November 26, 2022** |
| **OR** |
| &nbsp;&nbsp;&nbsp;&nbsp;**☐**&nbsp;&nbsp;&nbsp;&nbsp;**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| **For the transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** |

---

**Commission File Number: 1-5742**

### RITE AID CORPORATION
(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware**<br>(State or other jurisdiction of<br>incorporation or organization) | **23-1614034**<br>(I.R.S. Employer<br>Identification No.) |
| **PO Box 3165,Harrisburg, Pennsylvania**<br>(Address of principal executive offices) | **17105**<br>(Zip Code) |

---

Registrant's telephone number, including area code: **(717) 761-2633.**

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report):

 **1200 Intrepid Avenue, 2**<sup>nd</sup> **Floor,Philadelphia, Pennsylvania 19112**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $1.00 par value | RAD | New York Stock Exchange |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months, and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ⌧ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "Large Accelerated Filer," "Accelerated Filer," "Smaller Reporting Company" and "Emerging Growth Company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ⌧ Accelerated Filer ◻ Non-Accelerated Filer ◻ Smaller reporting company ☐Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange act). Yes ☐ No ⌧

The registrant had 56,523,354 shares of its $1.00 par value common stock outstanding as of December 20, 2022.

------

[**Table of Contents**](#TOC)

**RITE AID CORPORATION**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
|  | [Cautionary Statement Regarding Forward-Looking Statements](#CAUTIONARYSTATEMENTREGARDINGFORWARDLOOKI) | 3 |
|  | [**PART IFINANCIAL INFORMATION**](#PARTIFINANCIALINFORMATION_933247) |  |
| [ITEM 1.](#ITEM1FinancialStatements_606182) | [Financial Statements (unaudited):](#ITEM1FinancialStatements_606182) |  |
|  | [Condensed Consolidated Balance Sheets as of November 26, 2022 and February 26, 2022](#Cond_Consd_Balance_Sheets) | 6 |
|  | [Condensed Consolidated Statements of Operations for the Thirteen Week Periods Ended November 26, 2022 and November 27, 2021](#Cond_Consd_Stmt_Operations_13_Weeks) | 7 |
|  | [Condensed Consolidated Statements of Comprehensive Loss for the Thirteen Week Periods Ended November 26, 2022 and November 27, 2021](#Cond_Consd_Stmt_Compr_Income_13_Weeks) | 8 |
|  | [Condensed Consolidated Statements of Operations for the Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021](#Cond_Consd_Stmt_Operations_26_Weeks) | 9 |
|  | [Condensed Consolidated Statements of Comprehensive Loss for the Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021](#Cond_Consd_Stmt_Compr_Income_26_Weeks) | 10 |
|  | [Condensed Consolidated Statements of Stockholders' (Deficit) Equity for the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022](#Cond_Consd_Stmt_Equity_26_Weeks_2019) | 11 |
|  | [Condensed Consolidated Statements of Stockholders' (Deficit) Equity for the Thirteen and Thirty-Nine Week Periods Ended November 27, 2021](#Cond_Consd_Stmt_Equity_26_Weeks_2018) | 12 |
|  | [Condensed Consolidated Statements of Cash Flows for the Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021](#Cond_Consd_Stmt_Cash_Flows) | 13 |
|  | [Notes to Condensed Consolidated Financial Statements](#a1BasisofPresentation_981786) | 14 |
| [ITEM 2.](#ITEM2ManagementsDiscussionandAnalysisofF) | [Management's Discussion and Analysis of Financial Condition and Results](#ITEM2ManagementsDiscussionandAnalysisofF) | 46 |
| [ITEM 3.](#ITEM3QuantitativeandQualitativeDisclosur) | [Quantitative and Qualitative Disclosures About Market Risk](#ITEM3QuantitativeandQualitativeDisclosur) | 63 |
| [ITEM 4.](#ITEM4ControlsandProcedures_776111) | [Controls and Procedures](#ITEM4ControlsandProcedures_776111) | 64 |
|  | [**PART IIOTHER INFORMATION**](#PARTIIOTHERINFORMATION_329544) |  |
| [ITEM 1.](#ITEM1LegalProceedings_314172) | [Legal Proceedings](#ITEM1LegalProceedings_314172) | 65 |
| [ITEM 1A.](#ITEM1ARiskFactors_739347) | [Risk Factors](#ITEM1ARiskFactors_739347) | 65 |
| [ITEM 2.](#ITEM2UnregisteredSalesofEquitySecurities) | [Unregistered Sales of Equity Securities and Use of Proceeds](#ITEM2UnregisteredSalesofEquitySecurities) | 65 |
| [ITEM 3.](#ITEM3DefaultsUponSeniorSecurities_300759) | [Defaults Upon Senior Securities](#ITEM3DefaultsUponSeniorSecurities_300759) | 65 |
| [ITEM 4.](#ITEM4MineSafetyDisclosures_901475) | [Mine Safety Disclosures](#ITEM4MineSafetyDisclosures_901475) | 65 |
| [ITEM 5.](#ITEM5OtherInformation_37499) | [Other Information](#ITEM5OtherInformation_37499) | 65 |
| [ITEM 6.](#ITEM6Exhibits_728060) | [Exhibits](#ITEM6Exhibits_728060) | 65 |

---

[**Table of Contents**](#TOC)

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as "anticipate," "believe," "intend," "estimate," "expect," "continue," "should," "could," "may," "plan," "project," "predict," "will" and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies.

Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:

● the impact of widespread health developments, including the continued impact of the global coronavirus ("COVID-19") pandemic, the changing consumer behavior and preferences (including preferred shopping locations, vaccine hesitancy and the emergence of new variants), and the impact of those factors on the broader economy, financial and labor markets, wages, availability and access to credit and capital, our front-end and pharmacy operations and services, supply chain challenges including shipping delays, container and trucker shortages, port congestion and other logistics problems, our associates and executive and administrative personnel, our third-party service providers (including suppliers, vendors and business partners), and customers. In addition, continued shortages of pharmacists, pharmacy technicians and other employee turnover in the markets in which we operate, may inhibit our ability to maintain store hours at preferred levels. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations;

● our ability to successfully implement our RxEvolution strategy, attract and retain a sufficient number of our target consumers, integrate operations such as Elixir and any acquisitions, implement and integrate information technology and digital services, obtain permits required for store remodels, and improve the operating performance of our stores and pharmacy benefit management ("PBM") operations;

● our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms (including the impact of rising interest rates, market volatility, and continuing actions by the United States Federal Reserve), and our ability to satisfy our obligations and the other covenants contained in our credit and debt agreements;

● the nature, cost, impact and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations and actions, including those related to opioids, "usual and customary" pricing, government payer programs, business practices, or other matters;

● general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, including continued impacts of inflation or other pricing environment factors on our costs, liquidity and our ability to pass on price increases to our customers, including as a result of inflationary and deflationary pressures, a decline in consumer spending or deterioration in consumer financial position, whether due to inflation or other factors, as well as other factors specific to the markets in which we operate;

● the severity and resulting impact of the cough, cold and flu season;

● the impact on retail pharmacy business as PBM payors seek to reduce payments to retail pharmacies and incent or mandate movement away from retail pharmacies to PBM mail order pharmacies;

● our ability to achieve the benefits of our efforts to reduce the purchasing cost of our generic drugs;

● the risk that changes in federal or state laws or regulations, including to those relating to labor or wages, the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection or the Affordable Care Act (or "ACA"), and decisions of agencies and courts including the United States Supreme Court regarding those and other matters relevant to the Company or its operations, and any regulations enacted thereunder may occur;

[**Table of Contents**](#TOC)

● the impact of the loss of one or more major third party payor contracts and the risk that providers and state contract changes may occur;

● the risk that we may need to take further impairment charges if our future results do not meet our expectations;

● our ability to sell our Centers of Medicare and Medicaid Services ("CMS") receivables, in whole or in part, and on reasonably available terms, which could negatively impact our liquidity and leverage ratio if we do not consummate a sale;

● our ability to grow prescription count, realize front-end sales growth, and improve and grow the operations of our PBM;

● our ability to achieve cost savings and the other benefits of our organizational restructuring within our anticipated timeframe, if at all;

● decisions to close additional stores and distribution centers or undertake additional refinancing activities, which could result in further charges;

● our ability to manage expenses, our liquidity and our investments in working capital;

● the continued impact of gross margin pressure in the PBM industry due to continued consolidation and client demand for lower prices while providing enhanced service offerings;

● risks related to breaches of our (or our vendors') information or payment systems or unauthorized access to confidential or personal information of our associates or customers;

● our ability to maintain our current pharmacy services business and obtain new pharmacy services business and clients, including maintaining renewals of expiring contracts, avoiding contract termination rights that may permit certain of our clients to terminate their contracts prior to their expiration, early price renegotiations prior to contract expirations and the risk that we cannot meet client guarantees;

● our ability to manage our Medicare Part D Plan medical loss ratio ("MLR") and meet the financial obligations of the plan;

● the risk that we could experience deterioration in our current Star rating with the CMS or incur CMS penalties and/or sanctions;

● the expiration or termination of our Medicare or Medicaid managed care contracts by federal or state governments;

● changes in future exchange or interest rates (including the impact on our variable rate indebtedness) or credit ratings, changes in tax laws, regulations, rates and policies; and

● other risks and uncertainties described from time to time in our filings with the Securities and Exchange Commission (the "SEC").

[**Table of Contents**](#TOC)

We undertake no obligation to update or revise the forward-looking statements included in this report, whether as a result of new information, future events or otherwise, after the date of this report. Our actual results, performance or achievements could differ materially from the results expressed in, or implied by, these forward-looking statements. Factors that could cause or contribute to such differences are discussed in the section entitled "Management's Discussion and Analysis of Financial Condition and Results" included herein and in our Annual Report on Form 10-K for the fiscal year ended February 26, 2022 (the "Fiscal 2022 10-K"), which we filed with the SEC on April 25, 2022, our Quarterly Report on Form 10-Q for the thirteen weeks ended May 28, 2022, which we filed on July 6, 2022 and our Quarterly Report on Form 10-Q for the thirteen weeks ended August 27, 2022, which we filed on October 5, 2022, as well as in "Part I – Item 1A. Risk Factors" of the Fiscal 2022 10-K. To the extent that COVID-19 adversely affects our business and financial results, it may also have the effect of heightening many of the risk factors described herein and in our Fiscal 2022 10-K.

[**Table of Contents**](#TOC)

**PART I. FINANCIAL INFORMATION**

**ITEM 1. Financial Statements**

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands, except per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **November 26,**<br>**2022** | **February 26,**<br>**2022** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $103054 | $39721 |
| &nbsp;&nbsp;Accounts receivable, net | 1473997 | 1343496 |
| &nbsp;&nbsp;Inventories, net of LIFO reserve of $512,540 and $487,173 | 1981335 | 1959389 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 119836 | 106749 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 3678222 | 3449355 |
| Property, plant and equipment, net | 939648 | 989167 |
| Operating lease right-of-use assets | 2622969 | 2813535 |
| Goodwill | 626936 | 879136 |
| Other intangibles, net | 259954 | 291196 |
| Deferred tax assets | 13938 | 20071 |
| Other assets | 68107 | 86543 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $8209774 | $8529003 |
| **LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Current maturities of long-term debt and lease financing obligations | $6107 | $5544 |
| &nbsp;&nbsp;Accounts payable | 1454988 | 1571261 |
| &nbsp;&nbsp;Accrued salaries, wages and other current liabilities | 799555 | 780632 |
| &nbsp;&nbsp;Current portion of operating lease liabilities | 563490 | 575651 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 2824140 | 2933088 |
| Long-term debt, less current maturities | 3189013 | 2732986 |
| Long-term operating lease liabilities | 2427836 | 2597090 |
| Lease financing obligations, less current maturities | 12970 | 14830 |
| Other noncurrent liabilities | 159549 | 151976 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 8613508 | 8429970 |
| Commitments and contingencies |  |  |
| Total stockholders' (deficit) equity: |  |  |
| &nbsp;&nbsp;Common stock, par value $1 per share; 75,000 shares authorized; shares issued and outstanding 56,526 and 55,752 | 56526 | 55752 |
| &nbsp;&nbsp;Additional paid-in capital | 5915383 | 5910299 |
| &nbsp;&nbsp;Accumulated deficit | (6360206) | (5851581) |
| &nbsp;&nbsp;Accumulated other comprehensive loss | (15437) | (15437) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' (deficit) equity | (403734) | 99033 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' (deficit) equity | $8209774 | $8529003 |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Revenues | $6083346 | $6228880 |
| Costs and expenses: |  |  |
| &nbsp;&nbsp;Cost of revenues | 4879594 | 4894497 |
| &nbsp;&nbsp;Selling, general and administrative expenses | 1194546 | 1276920 |
| &nbsp;&nbsp;Facility exit and impairment charges | 22539 | 47455 |
| &nbsp;&nbsp;Interest expense | 57416 | 47794 |
| &nbsp;&nbsp;Gain on sale of assets, net | (3095) | (5899) |
| &nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |
|  | 6151000 | 6266113 |
| Loss before income taxes | (67654) | (37233) |
| Income tax benefit | (510) | (1175) |
| &nbsp;&nbsp;Net loss | $(67144) | $(36058) |
| Computation of loss attributable to common stockholders: |  |  |
| &nbsp;&nbsp;Net loss attributable to common stockholders—basic and diluted | $(67144) | $(36058) |
| &nbsp;&nbsp;Basic and diluted loss per share | $(1.23) | $(0.67) |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(In thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Net loss | $(67144) | $(36058) |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;Defined benefit pension plans: |  |  |
| &nbsp;&nbsp;Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $0 income tax expense |  | 123 |
| &nbsp;&nbsp;Total other comprehensive income |  | 123 |
| Comprehensive loss | $(67144) | $(35935) |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands, except per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Revenues | $17998997 | $18502865 |
| Costs and expenses: |  |  |
| &nbsp;&nbsp;Cost of revenues | 14444021 | 14637683 |
| &nbsp;&nbsp;Selling, general and administrative expenses | 3606028 | 3790035 |
| &nbsp;&nbsp;Facility exit and impairment charges | 134955 | 67639 |
| &nbsp;&nbsp;Goodwill and intangible asset impairment charges | 252200 |  |
| &nbsp;&nbsp;Interest expense | 158068 | 145507 |
| (Gain) loss on debt modifications and retirements, net | (41312) | 3235 |
| &nbsp;&nbsp;Gain on sale of assets, net | (61292) | (79) |
| &nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |
|  | 18492668 | 18649366 |
| Loss before income taxes | (493671) | (146501) |
| Income tax expense | 14954 | 2915 |
| Net loss | $(508625) | $(149416) |
| Computation of loss attributable to common stockholders: |  |  |
| &nbsp;&nbsp;Net loss attributable to common stockholders—basic and diluted | $(508625) | $(149416) |
| &nbsp;&nbsp;Basic and diluted loss per share | $(9.32) | $(2.77) |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(In thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Net loss | $(508625) | $(149416) |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;Defined benefit pension plans: |  |  |
| &nbsp;&nbsp;Amortization of net actuarial losses included in net periodic pension cost, net of $0 and $0 income tax expense |  | 369 |
| &nbsp;&nbsp;Change in fair value of interest rate cap |  | 27 |
| &nbsp;&nbsp;Total other comprehensive income |  | 396 |
| Comprehensive loss | $(508625) | $(149020) |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY**

**(In thousands, except per share amounts)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Total** |
| BALANCE FEBRUARY 26, 2022 | 55752 | $55752 | $5910299 | $(5851581) | $(15437) | $99033 |
| Net loss |  |  |  | (110191) |  | (110191) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Comprehensive loss |  |  |  |  |  | (110191) |
| Issuance of restricted stock | 61 | 61 | (61) |  |  |  |
| Exchange of restricted shares for taxes | (63) | (63) | (490) |  |  | (553) |
| Cancellation of restricted stock | (127) | (127) | 127 |  |  |  |
| Amortization of restricted stock balance |  |  | 3324 |  |  | 3324 |
| Stock-based compensation expense |  |  | 201 |  |  | 201 |
| Amortization of performance-based incentive plans |  |  | (190) |  |  | (190) |
| BALANCE MAY 28, 2022 | 55623 | 55623 | 5913210 | (5961772) | (15437) | (8376) |
| Net loss |  |  |  | (331290) |  | (331290) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Comprehensive loss |  |  |  |  |  | (331290) |
| Issuance of restricted stock | 1141 | 1141 | (1141) |  |  |  |
| Exchange of restricted shares for taxes | (182) | (182) | (1284) |  |  | (1466) |
| Cancellation of restricted stock | (2) | (2) | 2 |  |  |  |
| Amortization of restricted stock balance |  |  | 3323 |  |  | 3323 |
| Stock-based compensation expense |  |  | 111 |  |  | 111 |
| Amortization of performance-based incentive plans |  |  | 1300 |  |  | 1300 |
| BALANCE AUGUST 27, 2022 | 56580 | 56580 | 5915521 | (6293062) | (15437) | (336398) |
| Net loss |  |  |  | (67144) |  | (67144) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Comprehensive loss |  |  |  |  |  | (67144) |
| Exchange of restricted shares for taxes | (12) | (12) | (75) |  |  | (87) |
| Cancellation of restricted stock | (42) | (42) | 42 |  |  |  |
| Amortization of restricted stock balance |  |  | 2335 |  |  | 2335 |
| Stock-based compensation expense |  |  | 111 |  |  | 111 |
| Amortization of performance-based incentive plans |  |  | (2551) |  |  | (2551) |
| BALANCE NOVEMBER 26, 2022 | 56526 | $56526 | $5915383 | $(6360206) | $(15437) | $(403734) |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY**

**(In thousands, except per share amounts)**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | |
|  | **Shares** | **Amount** | <br>**Additional**<br>**Paid-In**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | **Accumulated**<br>**Other**<br>**Comprehensive**<br>**Loss** | <br>**Total** |
| BALANCE FEBRUARY 27, 2021 | 55143 | $55143 | $5897168 | $(5313103) | $(24054) | $615154 |
| Net loss |  |  |  | (13057) |  | (13057) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Changes in Defined Benefit Plans, net of $0 tax expense |  |  |  |  | 123 | 123 |
| Change in fair value of interest rate cap |  |  |  |  | 27 | 27 |
| Comprehensive loss |  |  |  |  |  | (12907) |
| Exchange of restricted shares for taxes | (2) | (2) | (33) |  |  | (35) |
| Cancellation of restricted stock | (48) | (48) | 48 |  |  |  |
| Amortization of restricted stock balance |  |  | 1618 |  |  | 1618 |
| Stock-based compensation expense |  |  | 150 |  |  | 150 |
| BALANCE MAY 29, 2021 | 55093 | 55093 | 5898951 | (5326160) | (23904) | 603980 |
| Net loss |  |  |  | (100301) |  | (100301) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Changes in Defined Benefit Plans, net of $0 tax expense |  |  |  |  | 123 | 123 |
| Comprehensive loss |  |  |  |  |  | (100178) |
| Issuance of restricted stock | 823 | 823 | (823) |  |  |  |
| Exchange of restricted shares for taxes | (146) | (146) | (2040) |  |  | (2186) |
| Cancellation of restricted stock | (38) | (38) | 38 |  |  |  |
| Amortization of restricted stock balance |  |  | 3519 |  |  | 3519 |
| Stock-based compensation expense |  |  | 150 |  |  | 150 |
| BALANCE AUGUST 28, 2021 | 55732 | 55732 | 5899795 | (5426461) | (23781) | 505285 |
| Net loss |  |  |  | (36058) |  | (36058) |
| Other comprehensive loss: |  |  |  |  |  |  |
| Changes in Defined Benefit Plans, net of $0 tax expense |  |  |  |  | 123 | 123 |
| Comprehensive loss |  |  |  |  |  | (35935) |
| Issuance of restricted stock | 81 | 81 | (81) |  |  |  |
| Exchange of restricted shares for taxes | (10) | (10) | (121) |  |  | (131) |
| Cancellation of restricted stock | (42) | (42) | 42 |  |  |  |
| Amortization of restricted stock balance |  |  | 2660 |  |  | 2660 |
| Stock-based compensation expense |  |  | 150 |  |  | 150 |
| BALANCE NOVEMBER 27, 2021 | 55761 | $55761 | $5902445 | $(5462519) | $(23658) | $472029 |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Operating activities: |  |  |
| &nbsp;&nbsp;Net loss | $(508625) | $(149416) |
| &nbsp;&nbsp;Adjustments to reconcile to net cash (used in) provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 208133 | 222691 |
| &nbsp;&nbsp;&nbsp;&nbsp;Facility exit and impairment charges | 134955 | 67639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangible asset impairment charges | 252200 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;LIFO charge | 25367 | 900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of assets, net | (61292) | (79) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in allowances for uncollectible accounts receivable | 7411 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 8635 | 8820 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on debt modifications and retirements, net | (41312) | 3235 |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in deferred taxes | 6133 | (1602) |
| &nbsp;&nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (149632) | (398079) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (47771) | (87150) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (99105) | 129436 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use assets and operating lease liabilities | (54551) | (19517) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets | (8935) | 34946 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 9537 | 219390 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by operating activities | (318852) | 36560 |
| Investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for property, plant and equipment | (172563) | (145001) |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets acquired | (24937) | (24289) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from insured loss |  | 10436 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from dispositions of assets and investments | 51030 | 7821 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale-leaseback transactions | 55894 | 39790 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (90576) | (111243) |
| Financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of long-term debt |  | 350000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net proceeds from revolver | 641000 | 300000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on long-term debt | (153068) | (544020) |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in zero balance cash accounts | (12184) | (15087) |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing fees paid for early debt redemption | (881) | (833) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for taxes related to net share settlement of equity awards | (2106) | (2352) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred financing costs paid |  | (18638) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 472761 | 69070 |
| Increase (decrease) in cash and cash equivalents | 63333 | (5613) |
| Cash and cash equivalents, beginning of period | 39721 | 160902 |
| Cash and cash equivalents, end of period | $103054 | $155289 |

---

See accompanying notes to condensed consolidated financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

**1. Basis of Presentation and Significant Accounting Policies**

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X, and therefore do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete annual financial statements. The accompanying financial information reflects all adjustments which are of a recurring nature and, in the opinion of management, are necessary for a fair presentation of the results for the interim periods. The results of operations for the thirteen and thirty-nine week periods ended November 26, 2022 are not necessarily indicative of the results to be expected for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Rite Aid Corporation ("Rite Aid") and Subsidiaries (together with Rite Aid, the "Company") Fiscal 2022 10-K.

***Revenue Recognition***

The following table disaggregates the Company's revenue by major source in each segment for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**In thousands** | **November 26,**<br>**2022**<br>**(13 weeks)** | **November 27,**<br>**2021**<br>**(13 weeks)** | **November 26,**<br>**2022**<br>**(39 weeks)** | **November 27,**<br>**2021**<br>**(39 weeks)** |
| Retail Pharmacy segment: |  |  |  |  |
| &nbsp;&nbsp;Pharmacy sales | $3155646 | $3132821 | $9180331 | $9069520 |
| &nbsp;&nbsp;Front-end sales | 1229547 | 1272342 | 3722343 | 3901285 |
| &nbsp;&nbsp;Other revenue | 27039 | 27345 | 86705 | 90603 |
| &nbsp;&nbsp;Total Retail Pharmacy segment | 4412232 | 4432508 | 12989379 | 13061408 |
| Pharmacy Services segment | 1726933 | 1858830 | 5180031 | 5629325 |
| &nbsp;&nbsp;Intersegment elimination | (55819) | (62458) | (170413) | (187868) |
| &nbsp;&nbsp;Total revenue | $6083346 | $6228880 | $17998997 | $18502865 |

---

The Retail Pharmacy segment offered a chain-wide loyalty card program titled wellness+. Individual customers were able to become members of the wellness+ program. Members participating in the wellness+ loyalty card program earned points on a calendar year basis for eligible front-end merchandise purchases and qualifying prescription purchases. The wellness+ program was terminated as of July 1, 2020, with benefits earned as of that date available to be used through the end of calendar year 2020. Beginning in December 2020, the Company granted temporary extensions of benefits to certain previous members that were eligible for a discount as of the end of each previous six month period such that those prior members were eligible to continue to receive that discount on purchases made through the subsequent six months with no additional purchase requirement. New and existing customers who were not already eligible for program benefits also had the opportunity to earn additional discounts on purchases made through each six month period. A final extension was granted on December 31, 2021 through February 26, 2022 at which point all discounts were terminated.

A new loyalty program, Rite Aid Rewards, was initiated on February 27, 2022. Customers that enroll in the new program earn points for each dollar spent on front of store purchases as well as for eligible pharmacy prescriptions. Points can then be converted into a "Rite Aid Rewards" coupon that can be tendered as payment in a future purchase.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

Each point is worth $0.002. Customers must accumulate 1,000 points and create an online account in order to convert earned points to a "Rite Aid Rewards" coupon. Unused/unconverted points expire after 90 days. Unredeemed "Rite Aid Rewards" coupons expire 30 days after conversion from points earned.

Points earned pursuant to the Rite Aid Rewards program represent a performance obligation. The value of unredeemed Rite Aid Rewards points is deferred as a contract liability (included in other current liabilities). As members redeem points in the form of a Rite Aid Rewards coupon or when points or unredeemed Rite Aid Rewards coupons expire, the Retail Pharmacy segment recognizes the redeemed/expired portion of the deferred contract liability into revenue. The Retail Pharmacy segment had accrued contract liabilities of $1,157 and $0 as of November 26, 2022 and February 26, 2022, respectively.

***Recently Adopted Accounting Pronouncements***

In December 2019, the FASB issued ASU 2019-12, *Simplifying the Accounting for Income Taxes (Topic 740)*. This ASU simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the recognition of deferred tax liabilities and the methodology for calculating income taxes in the interim period. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This ASU was effective for fiscal years beginning after December 15, 2020 (fiscal 2022). The Company adopted ASU 2019-12 effective February 28, 2021 and the adoption of this standard did not have a material impact on the Company's financial position.

**2. Acquisition**

On December 18, 2020, pursuant to that certain stock purchase agreement, dated as of October 7, 2020, by and between the Company and Bartell Drug Company ("Bartell"), the Company acquired Bartell (the "Acquisition"), a Washington corporation, for approximately $89,724 in cash, subject to certain customary post-closing working capital adjustments. The Company financed the Acquisition with borrowings under its Senior Secured Revolving Credit Facility together with cash on hand. Bartell operated 67 retail drug stores and one distribution center in the greater Seattle, Washington area. Bartell operates as a 100 percent owned subsidiary of the Company within its Retail Pharmacy segment.

The Company's condensed consolidated financial statements for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021 include Bartell's results of operations. The Company's condensed consolidated financial statements reflect the final purchase accounting adjustments in accordance with ASC 805 "Business Combinations", whereby the purchase price was allocated to the assets acquired and liabilities assumed based upon their estimated fair values on the Acquisition date.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The following allocation of the purchase price and the estimated transaction costs is final:

---

| | |
|:---|:---|
| ***Final purchase price*** |  |
| Cash consideration | $89724 |
| &nbsp;&nbsp;Total | 89724 |
| ***Final purchase price allocation*** |  |
| Cash and cash equivalents | $3494 |
| Accounts receivable | 23860 |
| Inventories | 67745 |
| Prepaid expenses and other current assets | 1857 |
| &nbsp;&nbsp;Total current assets | 96956 |
| Property and equipment | 28229 |
| Operating lease right-of-use assets | 143651 |
| Intangible assets<sup>(1)</sup> | 68700 |
| Other assets | 1805 |
| &nbsp;&nbsp;Total assets acquired | 339341 |
| Accounts payable | 24166 |
| Accrued salaries, wages and other current liabilities | 20335 |
| Current portion of operating lease liabilities | 24617 |
| &nbsp;&nbsp;Total current liabilities | 69118 |
| Long-term operating lease liabilities | 124023 |
| Other long-term liabilities | 166 |
| &nbsp;&nbsp;Total liabilities assumed | 193307 |
| Deferred tax liabilities recorded on purchase | 13951 |
| Net assets acquired | 132083 |
| Bargain purchase gain | (42359) |
| ***Total purchase price*** | $89724 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intangible assets are recorded at estimated fair value, as determined by management based on available information which includes a final valuation prepared by an independent third party. The fair values assigned to identifiable intangible assets were determined through the use of the income approach, specifically the relief from royalty and the multi-period excess earnings methods. The major assumptions used in arriving at the estimated identifiable intangible asset values included management's final estimates of future cash flows, discounted at an appropriate rate of return which are based on the weighted average cost of capital for both the Company and other market participants, projected customer attrition rates, as well as applicable royalty rates for comparable assets. The useful lives for intangible assets were determined based upon the remaining useful economic lives of the intangible assets that are expected to contribute directly or indirectly to future cash flows. The estimated fair value of intangible assets and related useful lives as included in the final purchase price allocation include:

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Estimated Fair Value** | **Estimated Useful Life (In Years)** |
| Prescription files | $54300 | 10 |
| Tradename | 14400 | Indefinite |
| &nbsp;&nbsp;Total | $68700 |  |

---

During the thirteen week period ended February 27, 2021, the Company recorded a gain on Bartell acquisition of $47,705 primarily due to fair value adjustments related to prescription files and the tradename compared to book values. During the thirteen week period ended November 27, 2021, in connection with determining its final purchase price allocation, the Company recorded a loss on Bartell acquisition of $5,346 primarily due to contract termination charges, inventory valuation adjustments and changes in deferred income taxes, resulting in a net bargain purchase gain of $42,359. The Company believes that the bargain purchase gain was primarily the result of the decision by the Bartell stockholders to sell their interests as Bartell had been experiencing increasing borrowings under its credit agreements to meet its operating needs and increasing net losses. The agreed upon purchase price reflected the fact the seller would have needed to incur further significant debt to cover the operating costs of Bartell, which would have required amendments to its credit arrangements. With the Company's existing infrastructure, scale and expertise, the Company believes that it has access to the necessary synergies to allow necessary operational improvements to be implemented more efficiently than the seller.

During the thirteen week periods ended November 26, 2022 and November 27, 2021, acquisition costs of $0 and $3,642 were expensed as incurred. During the thirty-nine week periods ended November 26, 2022 and November 27, 2021, acquisition costs of $0 and $12,119 were expensed as incurred.

**3. Restructuring**

Beginning in fiscal 2019, the Company initiated a series of restructuring plans designed to reorganize its executive management team, reduce managerial layers, and consolidate roles. In March 2020, the Company announced the details of its RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU's in its front-end offering to free up working capital and update its merchandise assortment, assessing its pricing and promotional strategy, rebranding its retail pharmacy and pharmacy services business, launching its Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across the enterprise. Other strategic initiatives include the expansion of the Company's digital business, replacing and updating the Company's financial systems to improve efficiency, and movement to a common client platform at Elixir. In April 2022, the Company announced further strategic initiatives to reduce costs through the closure of unprofitable stores, reduce corporate administration expenses, improve efficiencies in worked payroll and other store labor costs, engage in a comprehensive review of purchasing and other business processes in both the Retail Pharmacy and Pharmacy Services segments in order to identify areas of opportunity, as well as expense reductions at the Pharmacy Services segment. These and future restructuring activities are expected to provide future growth and expense efficiency benefits. There can be no assurance that the Company's current and future restructuring charges will achieve the cost savings and remerchandising benefits in the amounts or time anticipated.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

For the thirteen week period ended November 26, 2022, the Company incurred total restructuring-related costs of $26,500, which are included as a component of SG&A. These costs are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Retail Pharmacy**<br> **segment** | **Pharmacy**<br>**Services segment** | <br>**Total** |
| **Restructuring-related costs**  |  |  |  |
| Severance and related costs associated with ongoing reorganization efforts<sup>(a)</sup>  | $3242 | $1558 | $4800 |
| Professional and other fees relating to restructuring activities<sup>(b)</sup>  | 16634 | 5066 | 21700 |
| Total restructuring-related costs  | $19876 | $6624 | $26500 |

---

For the thirteen week period ended November 27, 2021, the Company incurred total restructuring-related costs of $9,657, which are included as a component of SG&A. These costs are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Retail Pharmacy**<br> **segment** | **Pharmacy**<br>**Services segment** | <br>**Total** |
| **Restructuring-related costs**  |  |  |  |
| Severance and related costs associated with ongoing reorganization efforts<sup>(a)</sup>  | $— | $97 | $97 |
| Professional and other fees relating to restructuring activities<sup>(b)</sup>  | 3746 | 5814 | 9560 |
| Total restructuring-related costs  | $3746 | $5911 | $9657 |

---

For the thirty-nine week period ended November 26, 2022, the Company incurred total restructuring-related costs of $61,951, which are included as a component of SG&A. These costs are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Retail Pharmacy**<br> **segment** | **Pharmacy**<br>**Services segment** | <br>**Total** |
| **Restructuring-related costs**  |  |  |  |
| Severance and related costs associated with ongoing reorganization efforts<sup>(a)</sup> | $15443 | $2174 | $17617 |
| Professional and other fees relating to restructuring activities<sup>(b)</sup> | 30246 | 14088 | 44334 |
| Total restructuring-related costs  | $45689 | $16262 | $61951 |

---

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

For the thirty-nine week period ended November 27, 2021, the Company incurred total restructuring-related costs of $25,173, which are included as a component of SG&A. These costs are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Retail Pharmacy**<br> **segment** | **Pharmacy**<br>**Services segment** | <br>**Total** |
| **Restructuring-related costs**  |  |  |  |
| Severance and related costs associated with ongoing reorganization efforts<sup>(a)</sup>  | $— | $1098 | $1098 |
| Professional and other fees relating to restructuring activities<sup>(b)</sup>  | 7951 | 16124 | 24075 |
| Total restructuring-related costs  | $7951 | $17222 | $25173 |

---

A summary of restructuring-related liabilities associated with the programs noted above, which are included in accrued salaries, wages and other current liabilities, is as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Severance and related**<br>**costs (a)** | **Professional and**<br>**other fees (b)** | <br>**Total** |
| Balance at February 26, 2022 | $4257 | $4463 | $8720 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions charged to expense  | 11904 | 10742 | 22646 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash payments  | (5231) | (11727) | (16958) |
| Balance at May 28, 2022 | $10930 | $3478 | $14408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions charged to expense  | 913 | 11892 | 12805 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash payments  | (2782) | (10066) | (12848) |
| Balance at August 27, 2022 | $9061 | $5304 | $14365 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions charged to expense  | 4800 | 21700 | 26500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash payments  | (4452) | (18297) | (22749) |
| Balance at November 26, 2022 | $9409 | $8707 | $18116 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) – Severance and related costs reflect severance accruals, executive search fees, outplacement services and other similar charges associated with ongoing reorganization efforts.

&nbsp;&nbsp;&nbsp;&nbsp;(b) – Professional and other fees include costs incurred in connection with the identification and implementation of initiatives associated with restructuring activities.

The Company anticipates incurring approximately $72,000 during fiscal 2023 in connection with its continued restructuring activities.

**4. Loss Per Share**

Basic loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the Company, subject to anti-dilution limitations.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| **Basic and diluted loss per share:** |  |  |  |  |
| Numerator: |  |  |  |  |
| &nbsp;&nbsp;Net loss attributable to common stockholders — basic and diluted | $(67144) | $(36058) | $(508625) | $(149416) |
| Denominator: |  |  |  |  |
| &nbsp;&nbsp;Basic and diluted weighted average shares | 54792 | 54168 | 54567 | 54004 |
| &nbsp;&nbsp;Basic and diluted loss per share | $(1.23) | $(0.67) | $(9.32) | $(2.77) |

---

Due to their antidilutive effect, 537 and 719 potential shares related to stock options have been excluded from the computation of diluted loss per share for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. Also, excluded from the computation of diluted loss per share for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021 are restricted shares of 1,724 and 1,583, respectively, which are included in shares outstanding.

**5. Facility Exit and Impairment Charges**

Facility exit and impairment charges consist of amounts as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period** | **Thirteen Week Period** | **Thirty-Nine Week Period** | **Thirty-Nine Week Period** |
|  | **Ended** | **Ended** | **Ended** | **Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| Impairment charges  | $7728 | $40323 | $77502 | $51372 |
| Facility exit charges  | 14811 | 7132 | 57453 | 16267 |
|  | $22539 | $47455 | $134955 | $67639 |

---

**Impairment Charges**

These amounts include the write-down of long-lived assets at locations that were assessed for impairment because of management's intention to relocate or close the location or because of changes in circumstances that indicated the carrying value of an asset may not be recoverable.

The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following:

● Level 1—Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

● Level 2—Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument.

● Level 3—Inputs to the valuation methodology are unobservable inputs based upon management's best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.

**Non-Financial Assets Measured on a Non-Recurring Basis**

Long-lived non-financial assets are measured at fair value on a nonrecurring basis for purposes of calculating impairment using Level 2 and Level 3 inputs as defined in the fair value hierarchy. The fair value of long-lived assets using Level 2 inputs is determined by evaluating the current economic conditions in the geographic area for similar use assets. The fair value of long-lived assets using Level 3 inputs is determined by estimating the amount and timing of net future cash flows (which are unobservable inputs) and discounting them using a risk-adjusted rate of interest (which is Level 1). The Company estimates future cash flows based on its experience and knowledge of the market in which the store is located. Significant increases or decreases in actual cash flows may result in valuation changes. During the thirty-nine week period ended November 26, 2022, long-lived assets with a carrying value of $94,713, primarily right-of-use assets in connection with stores or leased office spaces, were written down to their fair value of $17,211, resulting in an impairment charge of $77,502 of which $7,728 relates to the thirteen week period ended November 26, 2022. During the thirty-nine week period ended November 27, 2021, long-lived assets with a carrying value of $74,270, primarily right-of-use assets in connection with stores or leased office spaces, were written down to their fair value of $22,898, resulting in an impairment charge of $51,372 of which $40,323 related to the thirteen week period ended November 27, 2021. If our actual future cash flows differ from our projections materially, certain stores that are either not impaired or partially impaired in the current period may be further impaired in future periods.

The following table presents fair values for those assets measured at fair value on a non-recurring basis at November 26, 2022 and November 27, 2021:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br><br>**Level 1** | <br><br>**Level 2** | <br><br>**Level 3** | **Fair Values**<br>**as of** <br>**Impairment Date** | **Total**<br>**Charges**<br>**November 26, 2022** |
| Long-lived assets held for use | $— | $12096 | $— | $12096 | $(72670) |
| Long-lived assets held for sale | $— | $5115 | $— | $5115 | $(4832) |
| Total | $— | $17211 | $— | $17211 | $(77502) |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | <br><br>**Level 1** | <br><br>**Level 2** | <br><br>**Level 3** | **Fair Values**<br>**as of** <br>**Impairment Date** | **Total**<br>**Charges**<br>**November 27, 2021** |
| Long-lived assets held for use | $— | $— | $22898 | $22898 | $(51372) |
| Long-lived assets held for sale | $— | $— | $— | $— | $— |
| Total | $— | $— | $22898 | $22898 | $(51372) |

---

The above assets reflected in the caption 'Long-lived assets held for sale' have not been reclassified to assets held for sale due to their immateriality.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

**Facility Exit Charges**

As part of the Company's ongoing business activities, the Company assesses stores and distribution centers for potential closure or relocation. Decisions to close or relocate stores or distribution centers in future periods would result in facility exit charges and inventory liquidation charges, as well as impairment of assets at these locations. When a store or distribution center is closed, the Company records an expense for unrecoverable costs and accrues a liability equal to the present value at current credit adjusted risk-free interest rates of any anticipated executory costs which are not included within the store or distribution center's respective lease liability under Topic 842. Other store or distribution center closing and liquidation costs are expensed when incurred.

The following table reflects changes in the Company's closed store liability relating to closed store and distribution center charges for new closures, changes in assumptions and interest accretion:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period** | **Thirteen Week Period** | **Thirty-Nine Week Period** | **Thirty-Nine Week Period** |
|  | **Ended** | **Ended** | **Ended** | **Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| Balance—beginning of period | $41946 | $5611 | $18688 | $3443 |
| &nbsp;&nbsp;Provision for present value of executory costs for leases exited | 10477 | 3620 | 39792 | 5328 |
| &nbsp;&nbsp;Changes in assumptions and other adjustments | (3259) | 1387 | (3886) | 2880 |
| &nbsp;&nbsp;Interest accretion | 258 | 4 | 593 | 20 |
| &nbsp;&nbsp;Cash payments | (3818) | (3941) | (9583) | (4990) |
| Balance—end of period | $45604 | $6681 | $45604 | $6681 |

---

**6. Fair Value Measurements**

The Company utilizes the three-level valuation hierarchy as described in Note 5, *Facility Exit and Impairment Charges,* for the recognition and disclosure of fair value measurements.

Financial instruments other than long-term indebtedness include cash and cash equivalents, accounts receivable and accounts payable. These instruments are recorded at book value, which we believe approximate their fair values due to their short term nature. In addition, as of November 26, 2022, the Company has $7,696 of investments carried at amortized cost as these investments are being held to maturity, which are included as a component of prepaid expenses and other current assets. As of February 26, 2022, the Company has $7,406 of investments carried at amortized cost as these investments are being held to maturity, which are included as a component of other assets. The Company believes the carrying value of these investments approximates their fair value.

The fair value for LIBOR-based borrowings under the Company's senior secured credit facility is estimated based on the quoted market price of the financial instrument which is considered Level 1 of the fair value hierarchy. The fair values of substantially all of the Company's other long-term indebtedness are estimated based on quoted market prices of the financial instruments which are considered Level 1 of the fair value hierarchy. The carrying amount and estimated fair value of the Company's total long-term indebtedness was $3,189,013 and $2,686,945 respectively, as of

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

November 26, 2022. The carrying amount and estimated fair value of the Company's total long-term indebtedness was $2,732,986 and $2,661,122, respectively, as of February 26, 2022.

**7. Income Taxes**

The Company recorded an income tax benefit of $510 and $1,175 for the thirteen week periods ended November 26, 2022 and November 27, 2021, respectively. The Company recorded income tax expense of $14,954 and $2,915 for the thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. The effective tax rate for the thirteen week periods ended November 26, 2022 and November 27, 2021 was 0.8% and 3.2%, respectively. The effective tax rate for the thirty-nine week periods ended November 26, 2022 and November 27, 2021 was (3.0)% and (2.0)%, respectively. The effective tax rate for the thirteen and thirty-nine week periods ended November 26, 2022 was net of an adjustment of (19.5)% and 46.5%, respectively, to adjust the valuation allowance against deferred tax assets. The effective tax rate for the thirty-nine week period ended November 26, 2022 was primarily impacted by a Pennsylvania law change that reduced the statutory corporate net income tax rate, causing a reduction to the valuation allowance of $380,509. The effective tax rate for the thirteen and thirty-nine week periods ended November 27, 2021 was net of an adjustment of (18.5)% and (21.4)%, respectively, to adjust the valuation allowance against deferred tax assets.

The Company recognizes tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

The Company believes that it is reasonably possible that a decrease of up to $25,130 in unrecognized tax benefits related to state exposures may be necessary in the next twelve months; however, management does not expect the change to have a material impact on the results of operations or the financial position of the Company.

The Company regularly evaluates valuation allowances established for deferred tax assets for which future realization is uncertain. Management will continue to monitor all available evidence related to the net deferred tax assets that may change the most recent assessment, including events that have occurred or are anticipated to occur. The Company continues to maintain a valuation allowance against net deferred tax assets of $1,593,207 and $1,822,710, which relates to federal and state deferred tax assets that may not be realized based on the Company's future projections of taxable income at November 26, 2022 and February 26, 2022, respectively.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implemented a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases and several tax incentives to promote clean energy. Based on the Company's current analysis of the provisions, it does not believe that this legislation will have a material impact on the financial statements.

**8. Medicare Part D** 

The Company offers Medicare Part D benefits through Elixir Insurance ("EI"), which has contracted with CMS to be a Prescription Drug Plan ("PDP") and, pursuant to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, must be a risk-bearing entity regulated under state insurance laws or similar statutes.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

EI is a licensed domestic insurance company under the applicable laws and regulations. Pursuant to these laws and regulations, EI must file quarterly and annual reports with the National Association of Insurance Commissioners ("NAIC") and certain state regulators, must maintain certain minimum amounts of capital and surplus under formulas established by certain states and must, in certain circumstances, request and receive the approval of certain state regulators before making dividend payments or other capital distributions to the Company. The Company does not believe these limitations on dividends and distributions materially impact its financial position. EI is subject to minimum capital and surplus requirements in certain states. The minimum amount of capital and surplus required to satisfy regulatory requirements in these states is $11,383 as of September 30, 2022. EI was in excess of the minimum required amounts in these states as of November 26, 2022.

The Company has recorded estimates of various assets and liabilities arising from its participation in the Medicare Part D program based on information in its claims management and enrollment systems. Significant estimates arising from its participation in this program include: (i) estimates of low-income cost subsidies, reinsurance amounts, and coverage gap discount amounts ultimately payable to or receivable from CMS based on a detailed claims reconciliation that will occur in the following year; (ii) an estimate of amounts receivable from CMS under a risk-sharing feature of the Medicare Part D program design, referred to as the risk corridor; and (iii) estimates for claims that have been reported and are in the process of being paid or contested and for our estimate of claims that have been incurred but have not yet been reported.

On August 12, 2021, the Company entered into a receivable purchase agreement (the "August 2021 Receivable Purchase Agreement") with Bank of America, N.A. (the "Purchaser").

Pursuant to the terms and conditions set forth in the August 2021 Receivable Purchase Agreement, the Company sold $271,829, a portion of its calendar year 2021 CMS receivable, for $258,116, of which $239,360 was received on August 12, 2021. The remaining $18,756, which is included in accounts receivable, net as of November 26, 2022, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $13,713, which is included as a component of loss (gain) on sale of assets, net during the thirteen week period ended August 28, 2021.

On August 12, 2021, concurrent with the August 2021 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the "August 2021 Indemnity Agreement"), whereby the Company has agreed to indemnify, reimburse, and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the August 2021 Indemnity Agreement. Based on its evaluation of the August 2021 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the August 2021 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the August 2021 Indemnity Agreement.

On January 24, 2022, the Company entered into a receivable purchase agreement (the "January 2022 Receivable Purchase Agreement") with Purchaser.

Pursuant to the terms and conditions set forth in the January 2022 Receivable Purchase Agreement, the Company sold $400,680, a portion of its calendar 2021 CMS receivable, for $387,035, of which $359,388 was received on January 24, 2022. The remaining $27,647, which is included in accounts receivable, net as of November 26, 2022, is

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $13,645, which is included as a component of loss (gain) on sale of assets, net during the thirteen week period ended February 26, 2022.

On January 24, 2022, concurrent with the January 2022 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the "January 2022 Indemnity Agreement"), whereby the Company has agreed to indemnify, reimburse, and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the January 2022 Indemnity Agreement. Based on its evaluation of the January 2022 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the January 2022 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the January 2022 Indemnity Agreement.

On October 13, 2022, the Company entered into a receivable purchase agreement (the "October 2022 Receivable Purchase Agreement") with Purchaser.

Pursuant to the terms and conditions set forth in the October 2022 Receivable Purchase Agreement, the Company sold $195,487, a portion of its calendar 2022 CMS receivable, for $180,405, of which $166,917 was received on October 13, 2022. The remaining $13,488, which is included in accounts receivable, net as of November 26, 2022, is payable to the Company, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance from CMS. In connection therewith, the Company recognized a loss of $15,082, which is included as a component of gain on sale of assets, net during the thirteen week period ended November 26, 2022.

On October 13, 2022, concurrent with the October 2022 Receivable Purchase Agreement, the Company entered into an indemnity agreement (the "October 2022 Indemnity Agreement"), whereby the Company has agreed to indemnify, reimburse, and hold Purchaser harmless from certain liabilities and expenses actually suffered or incurred by the Purchaser resulting from the occurrence of certain events as specified in the October 2022 Indemnity Agreement. Based on its evaluation of the October 2022 Indemnity Agreement, the Company has determined that it is highly unlikely that the events covered under the October 2022 Indemnity Agreement would occur, and consequently, the Company has not recorded any indemnification liability associated with the October 2022 Indemnity Agreement.

During the thirteen week period ended November 26, 2022, the company incurred additional fees of $1,937, which are included as a component of gain on sale of assets, net related to the sale of the 2021 CMS receivable to Bank of America. The additional fees were incurred due to a CMS delay in settling the 2021 receivable.

As of November 26, 2022 and February 26, 2022 accounts receivable, net included $59,052 and $34,898 due from the Purchaser, subject to final CMS claim reconciliation adjustments, upon receipt of the final remittance for the respective calendar years from CMS.

As of November 26, 2022, and February 26, 2022, accounts receivable, net included $221,684 and $63,203 due from CMS.

The Inflation Reduction Act of 2022 contains several provisions affecting Medicare, which will take effect over various periods of time from 2023 to 2029. Based on the Company's current analysis of the provisions, it does not believe that this legislation will have a material impact on the financial statements.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

**9. Manufacturer Rebates Receivables**

The Pharmacy Services Segment has manufacturer rebates receivables due directly from manufacturers and from our rebate aggregator of $520,652 and $535,620 included in accounts receivable, net of an allowance for uncollectible rebates of $8,474 and $18,796, as of November 26, 2022 and February 26, 2022, respectively.

**10. Goodwill and Other Intangible Assets** 

Goodwill and indefinite-lived assets, such as certain trademarks acquired in connection with acquisition transactions, are not amortized, but are instead evaluated for impairment on an annual basis at the end of the fiscal year, or more frequently if events or circumstances indicate it may be more likely than not that the fair value of a reporting unit is less than its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill, the Company performs a quantitative goodwill impairment test. The fair value estimates used in the quantitative impairment test are calculated using an average of the income and market approaches. The income approach is based on the present value of future cash flows of each reporting unit, while the market approach is based on certain multiples of selected guideline public companies or selected guideline transactions. The approaches, which qualify as Level 3 within the fair value hierarchy, incorporate a number of market participant assumptions including future growth rates, discount rates, income tax rates and market activity in assessing fair value and are reporting unit specific. If the carrying amount exceeds the reporting unit's fair value, the Company recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. In addition, the Company considers the income tax effect of any tax deductible goodwill when measuring a goodwill impairment loss.

The goodwill related to the Pharmacy Services segment is at risk of future impairment if the fair value of this segment, and its associated assets, decrease in value due to further declines in its operating results or an inability to execute management's business strategies. Future cash flow estimates are, by their nature, subjective, and actual results may differ materially from the Company's estimates. If the Company's ongoing cash flow projections are not met or if market factors utilized in the impairment test deteriorate, including an unfavorable change in the terminal growth rate or the weighted-average cost of capital, the Company may have to record impairment charges in future periods.

During the thirteen week period ended August 27, 2022, the Company recorded a goodwill impairment charge of $252,200. As of November 26, 2022 and February 26, 2022, accumulated impairment losses for the Pharmacy Services segment was $1,055,912 and $803,712, respectively.

Below is a summary of the changes in the carrying amount of goodwill by segment for the thirty-nine week period ended November 26, 2022:

---

| | | | |
|:---|:---|:---|:---|
|  | **Retail** <br>**Pharmacy** | **Pharmacy** <br>**Services** | <br>**Total** |
| Balance, February 26, 2022 | 43492 | 835644 | 879136 |
| Goodwill impairment |  | (252200) | (252200) |
| Balance, November 26, 2022 | $43492 | $583444 | $626936 |

---

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The Company's intangible assets are primarily finite-lived and amortized over their useful lives. The following is a summary of the Company's finite-lived and indefinite-lived intangible assets as of November 26, 2022 and February 26, 2022.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **November 26, 2022** | **November 26, 2022** | **November 26, 2022** | **November 26, 2022** | **February 26, 2022** | **February 26, 2022** | **February 26, 2022** | **February 26, 2022** |
|  | <br>**Gross**<br>**Carrying**<br>**Amount** | <br>**Accumulated**<br>**Amortization** | <br>**Net** | **Remaining**<br>**Weighted**<br>**Average**<br>**Amortization**<br>**Period** | <br>**Gross**<br>**Carrying**<br>**Amount** | <br>**Accumulated**<br>**Amortization** | <br>**Net** | **Remaining**<br>**Weighted**<br>**Average**<br>**Amortization**<br>**Period** |
| Non-compete agreements and other<sup>(a)</sup> | $201669 | $(182641) | $19028 | 3<br> years | $197651 | $(178958) | $18693 | 3<br> years |
| Prescription files | 1030170 | (926017) | 104153 | 5<br> years | 1030169 | (918773) | 111396 | 6<br> years |
| Customer relationships<sup>(a)</sup> | 388000 | (301436) | 86564 | 9<br> years | 388000 | (286090) | 101910 | 10<br> years |
| CMS license | 57500 | (21691) | 35809 | 4<br> years | 57500 | (15372) | 42128 | 5<br> years |
| Claims adjudication and other developed software | 58985 | (58985) |  | 0<br> years | 58985 | (56316) | 2669 | 1<br> years |
| Backlog | 11500 | (11500) |  | 0<br> years | 11500 | (11500) |  | 0<br> years |
| Total finite | $1747824 | $(1502270) | 245554 |  | $1743805 | $(1467009) | $276796 |  |
| Trademarks | 14400 |  | 14400 | Indefinite | 14400 |  | 14400 | Indefinite |
| Total | $1762224 | $(1502270) | $259954 |  | $1758205 | $(1467009) | $291196 |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Amortized on an accelerated basis which is determined based on the remaining useful economic lives of the customer relationships that are expected to contribute directly or indirectly to future cash flows.

The Company is continuing to reposition its approach to the Elixir Insurance Part D business including an expectation of a purposeful shrinkage of the business. As a result, at the end of fiscal 2022, the Company adjusted the remaining amortization period of the CMS License to five years. Prior to such adjustment, the remaining life was nineteen years.

Amortization expense for these intangible assets and liabilities was $17,622 and $56,668 for the thirteen and thirty-nine week periods ended November 26, 2022, respectively. Amortization expense for these intangible assets and liabilities was $18,780 and $59,193 for the thirteen and thirty-nine week periods ended November 27, 2021, respectively. The anticipated annual amortization expense for these intangible assets and liabilities is 2023—$72,374; 2024—$60,009; 2025—$48,764; 2026—$38,301 and 2027—$31,309.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

**11. Indebtedness and Credit Agreement**

Following is a summary of indebtedness and lease financing obligations at November 26, 2022 and February 26, 2022:

---

| | | |
|:---|:---|:---|
|  | **November 26,**<br>**2022** | **February 26,**<br>**2022** |
| Secured Debt: |  |  |
| &nbsp;&nbsp;Senior secured revolving credit facility due August 2026 ($1,350,000 and $709,000 face value less unamortized debt issuance costs of $14,956 and $18,010) | 1335044 | 690990 |
| &nbsp;&nbsp;FILO Term Loan due August 2026 ($350,000 face value less unamortized debt issuance costs of $1,946 and $2,344) | 348054 | 347656 |
|  | 1683098 | 1038646 |
| Second Lien Secured Debt: |  |  |
| &nbsp;&nbsp;7.5% senior secured notes due July 2025 ($485,058 and $600,000 face value less unamortized debt issuance costs of $4,278 and $6,824) | 480780 | 593176 |
| &nbsp;&nbsp;8.0% senior secured notes due November 2026 ($849,918 face value less unamortized debt issuance costs of $12,088 and $14,397) | 837830 | 835521 |
|  | 1318610 | 1428697 |
| Unguaranteed Unsecured Debt: |  |  |
| &nbsp;&nbsp;7.7% notes due February 2027 ($185,691 and $237,386 face value less unamortized debt issuance costs of $426 and $642) | 185265 | 236744 |
| &nbsp;&nbsp;6.875% fixed-rate senior notes due December 2028 ($2,046 and $29,001 face value less unamortized debt issuance costs of $6 and $102) | 2040 | 28899 |
|  | 187305 | 265643 |
| Lease financing obligations | 19077 | 20374 |
| Total debt | 3208090 | 2753360 |
| Current maturities of long-term debt and lease financing obligations | (6107) | (5544) |
| Long-term debt and lease financing obligations, less current maturities | $3201983 | $2747816 |

---

***Credit Facility***

On December 20, 2018, the Company entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the "Credit Agreement"; and the Credit Agreement, as further amended by the Second Amendment (as defined below), the "Amended Credit Agreement"), which Credit Agreement provided for facilities consisting of a $2,700,000 senior secured asset-based revolving credit facility ("Initial Senior Secured Revolving Credit Facility") and a $450,000 "first-in, last-out" senior secured term loan facility ("Initial Senior Secured Term Loan," and together with the Initial Senior Secured Revolving Credit Facility, collectively, the "Initial Facilities"). In December 2018, the Company used proceeds from the Initial Facilities to refinance its prior $2,700,000 existing credit agreement.

On August 20, 2021, the Company entered into the Second Amendment to Credit Agreement (the "Second Amendment"), which, among other things, amended the Credit Agreement to provide for a $2,800,000 senior secured asset-based revolving credit facility ("Senior Secured Revolving Credit Facility" or "revolver") and a $350,000 "first-in,

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

last-out" senior secured term loan facility ("Senior Secured Term Loan" or "Term Loan" and together with the Senior Secured Revolving Credit Facility, collectively, the "Amended Facilities") and incorporate customary "hardwired" LIBOR transition provisions. The Amended Facilities extended the Company's debt maturity profile and provided additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bore interest at a rate per annum equal to, at the Company's option, a base rate (determined in a customary manner) plus a margin of between 0.25% to 0.75% or (y) an adjusted LIBOR rate (determined in a customary manner) plus a margin of between 1.25% and 1.75%, in each case based upon the Average ABL Availability (as defined in the Amended Credit Agreement). Borrowings under the Senior Secured Term Loan bore interest at a rate per annum equal to, at the Company's option, (x) a base rate (determined in a customary manner) plus a margin of 1.75% or (y) an adjusted LIBOR rate (determined in a customary manner) plus a margin of 2.75%.

The Company is required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability (as defined in the Amended Credit Agreement). The Amended Facilities were scheduled to mature on August 20, 2026 (subject to a springing maturity if certain of the Company's existing secured notes are not refinanced or repaid prior to the date that is 91 days prior to the stated maturity thereof).

The Company's borrowing capacity under the Senior Secured Revolving Credit Facility was based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At November 26, 2022, the Company had $1,700,000 of borrowings outstanding under the Amended Facilities and had letters of credit outstanding under the Senior Secured Revolving Credit Facility in a face amount of $175,911, which resulted in remaining borrowing capacity under the Senior Secured Revolving Credit Facility of $1,274,089. If at any time the total credit exposure outstanding under the Senior Secured Revolving Credit Facility exceeded the borrowing base, the Company would be required to repay amounts outstanding to eliminate such shortfall.

The Amended Credit Agreement restricted the Company and all of its subsidiaries that guaranteed its obligations under the Amended Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the "Subsidiary Guarantors") from accumulating cash on hand in excess of $200,000 at any time when revolving loans were outstanding (not including cash located in store and lockbox deposit accounts and cash necessary to cover current liabilities). The Amended Credit Agreement also stated that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default existed under the Amended Facilities or (ii) the sum of the Company's borrowing capacity under the Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account was less than or equal to $275,000 for three consecutive business days or less than or equal to $200,000 on any day (a "cash sweep period"), the funds in the Company's deposit accounts would be swept to a concentration account with the senior collateral agent and would be applied first to repay outstanding revolving loans under the Amended Facilities, and then held as collateral for the senior obligations until such cash sweep period was rescinded pursuant to the terms of the Amended Facilities.

With the exception of EI, substantially all of the Company's 100% owned subsidiaries guaranteed the obligations under the Amended Facilities, the secured guaranteed notes and unsecured guaranteed notes. The Company's obligations under the Amended Facilities and the Subsidiary Guarantors' obligations under the related guarantees were secured by (i) a first-priority lien on all of the Subsidiary Guarantors' cash and cash equivalents, accounts receivable,

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the "ABL priority collateral") and (ii) a second-priority lien on all of the Subsidiary Guarantors' equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that did not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations. The subsidiary guarantees related to the Company's Amended Facilities, the secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, were full and unconditional and joint and several. The Company had no independent assets or operations. Other than EI, the subsidiaries, including joint ventures, that did not guarantee the Amended Facilities and applicable notes, were minor.

The Amended Credit Agreement allowed the Company to have outstanding, at any time, up to an aggregate principal amount of $1,500,000 in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Amended Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock matured or required scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Amended Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that was 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Amended Credit Agreement additionally allowed the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Amended Credit Agreement) was not in effect; provided, however, that certain of the Company's other outstanding indebtedness limited the amount of unsecured debt that could be incurred if certain interest coverage levels were not met at the time of incurrence or other exemptions are not available. The Amended Credit Agreement also contained certain restrictions on the amount of secured first priority debt the Company was able to incur. The Amended Credit Agreement also allowed for the voluntary repurchase of any debt or other convertible debt, so long as the Amended Facilities were not in default and the Company maintained availability under its revolver of more than $365,000.

The Amended Credit Agreement had a financial covenant that required the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility was less than $200,000 or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility was less than $250,000 and, in each case, ending on and excluding the first day thereafter, if any, which was the 30th consecutive calendar day on which availability under the revolver was equal to or greater than $250,000. As of November 26, 2022, the availability under the Senior Secured Revolving Credit Facility was at a level that did not trigger the Amended Credit Agreement's financial covenant. The Amended Credit Agreement also contained covenants which placed restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Amended Credit Agreement provided for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It would also be an event of default if the Company failed to make any required payment on debt having a principal amount in excess of $50,000 or any event occurred that enabled, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment, repurchase, redemption or defeasance of such debt.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

On December 1, 2022, the Company entered into the Third Amendment to Credit Agreement (the "Third Amendment"), which, among other things, amended the Amended Credit Agreement (the Amended Credit Agreement, as modified by the Third Amendment, the "Currently Effective Credit Agreement") to provide for a $2,850,000 senior secured asset-based revolving credit facility (the "Currently Effective Senior Secured Revolving Credit Facility") and a $400,000 "first-in, last-out" senior secured term loan facility (the "Currently Effective Senior Secured Term Loan" and, together with the Currently Effective Senior Secured Revolving Credit Facility, collectively, the "Currently Effective Facilities"), replaced the LIBOR rate with a Term SOFR-based rate as the applicable benchmark for the Currently Effective Facilities, include COVID-19 vaccines in the borrowing base under the Currently Effective Senior Secured Revolving Credit Facility, subject to limitations and conditions as specified in the Currently Effective Credit Agreement, and increased the interest rate applicable to loans under the Currently Effective Senior Secured Term Loan to (x) a base rate (determined in a customary manner) plus a margin of 2.00% or (y) an adjusted Term SOFR-based rate (determined in a customary manner) plus a margin of 3.00%.

The Company is required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Currently Effective Senior Secured Revolving Credit Facility, depending on Average ABL Availability (as defined in the Currently Effective Credit Agreement). The Currently Effective Facilities are scheduled to mature on August 20, 2026 (subject to a springing maturity if certain of the Company's existing secured notes are not refinanced or repaid prior to the date that is 91 days prior to the stated maturity thereof).

The Company's borrowing capacity under the Currently Effective Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. If at any time the total credit exposure outstanding under the Currently Effective Senior Secured Revolving Credit Facility exceeds the borrowing base, the Company will be required to repay amounts outstanding to eliminate such shortfall.

The Currently Effective Credit Agreement restricts the Company and all of its subsidiaries that guarantee its obligations under the Currently Effective Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the "Subsidiary Guarantors") from accumulating cash on hand in excess of $200,000 at any time when revolving loans are outstanding (not including cash located in store and lockbox deposit accounts and cash necessary to cover current liabilities). The Currently Effective Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Currently Effective Facilities or (ii) the sum of the Company's borrowing capacity under the Currently Effective Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than or equal to $283,250 for three consecutive business days or less than or equal to $206,000 on any day (a "cash sweep period"), the funds in the Company's deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Currently Effective Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Currently Effective Facilities.

With the exception of EI, substantially all of the Company's 100% owned subsidiaries guarantee the obligations under the Currently Effective Facilities, the secured guaranteed notes and unsecured guaranteed notes. The Company's obligations under the Currently Effective Facilities and the Subsidiary Guarantors' obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors' cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

Currently Effective Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the "ABL priority collateral") and (ii) a second-priority lien on all of the Subsidiary Guarantors' equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Currently Effective Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations. The subsidiary guarantees related to the Company's Currently Effective Facilities, the secured guaranteed notes and, on an unsecured basis, the unsecured guaranteed notes, are full and unconditional and joint and several. The Company has no independent assets or operations. Other than EI, the subsidiaries, including joint ventures, that do not guarantee the Currently Effective Facilities and applicable notes, are minor.

The Currently Effective Credit Agreement allows the Company to have outstanding, at any time, up to an aggregate principal amount of $1,500,000 in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Currently Effective Facilities and existing indebtedness, provided that not in excess of $750,000 of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Currently Effective Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Currently Effective Credit Agreement additionally allows the Company to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Currently Effective Credit Agreement) is not in effect; provided, however, that certain of the Company's other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Currently Effective Credit Agreement also contains certain restrictions on the amount of secured first priority debt the Company is able to incur. The Currently Effective Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Currently Effective Facilities are not in default and the Company maintains availability under its revolver of more than $375,950.

The Currently Effective Credit Agreement has a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Currently Effective Senior Secured Revolving Credit Facility is less than $206,000 or (ii) on the third consecutive business day on which availability under the Currently Effective Senior Secured Revolving Credit Facility is less than $257,500 and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $257,500. The Currently Effective Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Currently Effective Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if the Company fails to make any required payment on debt having a principal amount in excess of $50,000 or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment, repurchase, redemption or defeasance of such debt.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

***Fiscal 2022 and 2023 Transactions***

On April 28, 2021, the Company issued a notice of redemption for all of the 6.125% Notes that were outstanding on May 28, 2021, pursuant to the terms of the indenture of the 6.125% Notes. On May 28, 2021, the Company redeemed 100% of the remaining outstanding 6.125% Notes at par. In connection therewith, the Company recorded a loss on debt retirement of $396 which included unamortized debt issuance costs. The debt repayment and related loss on debt retirement is included in the results of operations and cash flows.

On August 20, 2021, the Company entered into the Second Amendment in order to, among other things, increase the aggregate principal amount of commitments under the Senior Secured Revolving Credit Facility from $2,700,000 to $2,800,000 and decrease the aggregate principal amount of loans outstanding under the Senior Secured Term Loan from $450,000 to $350,000. In connection therewith, the Company recorded a loss on debt modification and retirement of $2,839 which included unamortized debt issuance costs. The debt repayment and related loss on debt modification and retirement is included in the results of operations and cash flows.

On June 13, 2022, the Company commenced a series of cash tender offers to purchase up to $150,000 aggregate principal amount of the Company's 7.50% Senior Secured Notes due 2025 (the "2025 Notes"), 8.0% Senior Secured Notes due 2026, 7.70% Notes due 2027 (the "2027 Notes") and 6.875% Notes due 2028 (the "2028 Notes"), subject to prioritized acceptance levels, a subcap of $100,000 with respect to the 2025 Notes and proration. On June 29, 2022, pursuant to an early settlement, the Company purchased an aggregate principal amount of $114,942 of its 2025 Notes, $51,695 aggregate principal amount of its 2027 Notes and $26,955 aggregate principal amount of its 2028 Notes. In connection therewith, the Company recorded a gain on debt retirement of $41,312, which included unamortized debt issuance costs. The debt repayment and related gain on debt retirement is included in the results of operations and cash flows.

On November 3, 2022, the Company announced the commencement of a cash tender offer to purchase up to $200,000 aggregate purchase price (not including any accrued and unpaid interest) of the Company's 2025 Notes, subject to proration. On November 30, 2022, pursuant to an early settlement, the Company purchased an aggregate principal amount of $160,497 of its 2025 Notes and on December 9, 2022, pursuant to the final settlement, the Company purchased an additional aggregate principal amount of $4,559 of its 2025 Notes. The Company anticipates that these purchases will be considered a debt retirement and accordingly, anticipates a gain on debt retirement of approximately $40,000 during the fourth quarter of fiscal 2023. As a result of the latest tender, the current outstanding amount of the Company's 2025 Notes is $320,002.

On December 1, 2022, the Company entered into the Third Amendment in order to, among other things, increase the aggregate principal amount of commitments under the Senior Secured Revolving Credit Facility from $2,800,000 to $2,850,000 and increase the aggregate principal amount of loans outstanding under the Senior Secured Term Loan from $350,000 to $400,000. As a result of the Third Amendment, the Company has increased its liquidity by $100,000. In connection therewith, the Company anticipates a loss on debt modification and retirement of less than $1,000, which includes unamortized debt issuance costs. The related loss on debt modification and retirement will be included in the results of operations and cash flows during the fourth quarter of fiscal 2023.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

***Maturities***

The aggregate annual principal payments of long-term debt for the remainder of fiscal 2023 and thereafter are as follows: 2023—$0; 2024—$0; 2025—$0; 2026—$485,058; 2027—$2,735,609 and $2,046 thereafter.

**12. Leases**

The Company leases most of its retail stores and certain distribution facilities under noncancelable operating and finance leases, most of which have initial lease terms ranging from 5 to 22 years. The Company also leases certain of its equipment and other assets under noncancelable operating leases with initial terms ranging from 3 to 10 years. In addition to minimum rental payments, certain store leases require additional payments based on sales volume, as well as reimbursements for taxes, maintenance and insurance. Most leases contain renewal options, certain of which involve rent increases.

The following table is a summary of the Company's components of net lease cost for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** | **November 26, 2022** | **November 27, 2021** |
| Operating lease cost  | $156779 | $167224 | $474580 | $505192 |
| Financing lease cost: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use asset  | 894 | 876 | 2566 | 2807 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest on long-term finance lease liabilities  | 477 | 533 | 1481 | 1652 |
| Total finance lease costs  | $1371 | $1409 | $4047 | $4459 |
| Short-term lease costs  | 1218 | 516 | 2260 | 2611 |
| Variable lease costs  | 43761 | 44417 | 130058 | 134603 |
| Less: sublease income  | (3098) | (3404) | (9714) | (10174) |
| Net lease cost  | $200031 | $210162 | $601231 | $636691 |

---

Supplemental cash flow information related to leases for the thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | |
|:---|:---|:---|
|  | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Cash paid for amounts included in the measurement of lease liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows paid for operating leases  | $524417 | $528035 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating cash flows paid for interest portion of finance leases  | 1481 | 1652 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing cash flows paid for principal portion of finance leases  | 2968 | 3146 |
| Right-of-use assets obtained in exchange for lease obligations: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating leases  | 217515 | 262937 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance leases  |  |  |

---

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

Supplemental balance sheet information related to leases as of November 26, 2022 and February 26, 2022 (in thousands, except lease term and discount rate):

---

| | | |
|:---|:---|:---|
|  | **November 26,**<br>**2022** | **February 26,**<br>**2022** |
| **Operating leases:** |  |  |
| Operating lease right-of-use asset  | $2622969 | $2813535 |
| Short-term operating lease liabilities  | $563490 | $575651 |
| Long-term operating lease liabilities  | 2427836 | 2597090 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating lease liabilities  | $2991326 | $3172741 |
| **Finance leases:** |  |  |
| Property, plant and equipment, net  | $13560 | $13950 |
| Current maturities of long-term debt and lease financing obligations  | $6107 | $5544 |
| Lease financing obligations, less current maturities  | 12970 | 14830 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total finance lease liabilities  | $19077 | $20374 |
| **Weighted average remaining lease term**  |  |  |
| Operating leases  | 7.5 | 7.7 |
| Finance leases  | 8.3 | 8.7 |
| **Weighted average discount rate**  |  |  |
| Operating leases  | 6.3% | 6.0% |
| Finance leases  | 9.1% | 10.0% |

---

The following table summarizes the maturity of lease liabilities under finance and operating leases as of November 26, 2022:

---

| | | | |
|:---|:---|:---|:---|
| | **November 26, 2022** | **November 26, 2022** | **November 26, 2022** |
| <br>**Fiscal year** | **Finance**<br>**Leases** | **Operating**<br> **Leases**<sup>(1)</sup> | <br>**Total** |
| 2023 (remaining fourteen weeks) | $4343 | $230437 | $234780 |
| 2024 | 6394 | 668106 | 674500 |
| 2025 | 2672 | 582738 | 585410 |
| 2026 | 1680 | 494887 | 496567 |
| 2027 | 1500 | 413327 | 414827 |
| Thereafter  | 11297 | 1449088 | 1460385 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease payments  | 27886 | 3838583 | 3866469 |
| Less: imputed interest  | (8809) | (847257) | (856066) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities  | $19077 | $2991326 | $3010403 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) – Future operating lease payments have not been reduced by minimum sublease rentals of $26 million due in the future under noncancelable leases.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

During the thirteen week period ended November 26, 2022, the Company sold four owned and operated retail stores to independent third parties. During the thirty-nine week period ended November 26, 2022, the Company sold seven owned and operated properties, including the Pontiac, MI and Liverpool, NY distribution centers and five retail stores to independent third parties. Net proceeds from the sales were $9,908 and $55,894 for the thirteen and thirty-nine week periods ended November 26, 2022, respectively. Concurrent with these sales, the Company entered into agreements to lease the properties back from the purchasers over a minimum lease term of 15 years for the retail stores and over a minimum lease term of three years for the distribution centers. The Company accounted for these leases as operating lease right-of-use assets and corresponding operating lease liabilities in accordance with the Lease Standard. The transactions resulted in a gain of $6,616 and $29,929 which is included in the gain on sale of assets, net for the thirteen and thirty-nine week periods ended November 26, 2022, respectively.

During the thirteen and thirty-nine week periods ended November 27, 2021, the Company sold nine and thirteen owned and operated stores to independent third parties. Net proceeds from the sales were $25,605 and $39,790 for the thirteen and thirty-nine week periods ended November 27, 2021, respectively. Concurrent with these sales, the Company entered into agreements to lease the properties back from the purchasers over a minimum lease term of 15 years. The Company accounted for these leases as operating lease right-of-use assets and corresponding operating lease liabilities in accordance with the Lease Standard. The transactions resulted in gains of $4,884 and $5,794 which is included in the gain on sale of assets, net for the thirteen and thirty-nine week periods ended November 27, 2021, respectively.

The Company has additional capacity under its outstanding debt agreements to enter into additional sale-leaseback transactions.

**13. Stock Options and Stock Awards**

The Company recognizes stock-based compensation expense over the requisite service period of the award, net of an estimate for the impact of forfeitures. Operating results for the thirty-nine week periods ended November 26, 2022 and November 27, 2021 include $8,635 and $8,820, respectively, of compensation costs related to the Company's stock-based compensation arrangements.

The total number and type of newly awarded grants and the related weighted average fair value for the thirty-nine week periods ended November 26, 2022 and November 27, 2021 are as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **November 26, 2022** | **November 26, 2022** | **November 27, 2021** | **November 27, 2021** |
|  | **Shares** | **Weighted Average Fair Value** | **Shares** | **Weighted Average Fair Value** |
| Stock options granted |  | $N/A |  | $N/A |
| Restricted stock awards granted | 1202 | $7.74 | 904 | $15.15 |
| Total awards | 1202 |  | 904 |  |

---

Typically, stock options vest, and are subsequently exercisable in equal annual installments over a four-year period for employees. Restricted stock awards typically vest in equal annual installments over a three-year period.

The Company calculates the fair value of stock options using the Black-Scholes-Merton option pricing model.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The Company also provides certain of its associates with performance based incentive awards under its equity incentive plans, pursuant to which the associates will receive a certain number of shares of the Company's common stock based on the Company meeting certain financial and performance goals. If such goals are not met, no stock-based compensation expense is recognized and any recognized stock-based compensation expense is reversed. During the thirty-nine week periods ended November 26, 2022 and November 27, 2021, the Company recorded a benefit of $771 and expense of $573, respectively, related to these performance based incentive awards under the Company's equity incentive plans, which is recorded as a component of stock-based compensation expense.

As of November 26, 2022, the total unrecognized pre-tax compensation costs related to unvested stock options, restricted stock and performance shares granted, net of forfeitures, and the weighted average period of cost amortization are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **November 26, 2022** | **November 26, 2022** | **November 26, 2022** |
|  | **Unvested**<br>**stock**<br>**options** | **Unvested**<br>**restricted**<br>**stock** | **Unvested**<br>**performance**<br>**shares** |
| Unrecognized pre-tax costs | $297 | $14664 | $6732 |
| Weighted average amortization period | 0.7 years | 2.0 years | 1.9 years |

---

**14. Retirement Plans**

Net periodic pension expense (income) for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021, for the Company's defined benefit plan includes the following components:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Defined Benefit** | **Defined Benefit** | **Defined Benefit** | **Defined Benefit** |
|  | **Pension Plan** | **Pension Plan** | **Pension Plan** | **Pension Plan** |
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| Service cost | $141 | $128 | $355 | $384 |
| Interest cost | 2028 | 1232 | 4555 | 3696 |
| Expected return on plan assets | (2113) | (1313) | (4917) | (3939) |
| Amortization of unrecognized net loss |  | 123 |  | 369 |
| Net periodic pension expense (income) | $56 | $170 | $(7) | $510 |

---

The Company is not required to make any contributions to its company-sponsored pension plans in fiscal 2023 but may make contributions to the extent such contributions are beneficial to the Company. The Company did not make any contributions to its company-sponsored pension plans in the first three quarters of fiscal 2023.

**15. Segment Reporting** 

The Company has two reportable segments, its retail drug stores ("Retail Pharmacy"), and its pharmacy services ("Pharmacy Services") segments.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The Retail Pharmacy segment's primary business is the sale of prescription drugs and related consultation to its customers. Additionally, the Retail Pharmacy segment sells a full selection of health and beauty aids and personal care products, seasonal merchandise and a large private brand product line. The Pharmacy Services segment offers a full range of pharmacy benefit management services including plan design and administration, formulary management and claims processing. Additionally, the Pharmacy Services segment offers specialty and mail order services, and drug benefits to eligible beneficiaries under the federal government's Medicare Part D program.

The Company's chief operating decision makers are its Chief Executive Officer, Chief Financial Officer and several other members of the Executive Leadership Team, (collectively the "CODM"). The CODM has ultimate responsibility for enterprise decisions. The CODM determines, in particular, resource allocation for, and monitors performance of, the consolidated enterprise, the Retail Pharmacy segment and the Pharmacy Services segment. The Retail Pharmacy and Pharmacy Services segment managers have responsibility for operating decisions, allocating resources and assessing performance within their respective segments. The CODM relies on internal management reporting that analyzes enterprise results on certain key performance indicators, namely, revenues, gross profit, and Adjusted EBITDA.

The following is balance sheet information for the Company's reportable segments:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Retail**<br>**Pharmacy** | **Pharmacy**<br>**Services** | <br>**Eliminations**<sup>(1)</sup> | <br>**Consolidated** |
| **November 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;Total Assets | $5962934 | $2261550 | $(14710) | $8209774 |
| &nbsp;&nbsp;Goodwill | 43492 | 583444 |  | 626936 |
| **February 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;Total Assets | $6068594 | $2482232 | $(21823) | $8529003 |
| &nbsp;&nbsp;Goodwill | 43492 | 835644 |  | 879136 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) As of November 26, 2022 and February 26, 2022, intersegment eliminations include intersegment accounts receivable of $14,710 and $21,823 , respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The following table is a reconciliation of the Company's business segments to the consolidated financial statements for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Retail**<br>**Pharmacy** | **Pharmacy**<br>**Services** | **Intersegment**<br>**Eliminations**<sup>(1)</sup> | <br>**Consolidated** |
| **Thirteen Week Period Ended** |  |  |  |  |
| &nbsp;&nbsp;**November 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $4412232 | $1726933 | $(55819) | $6083346 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 1099279 | 104473 |  | 1203752 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(2)</sup> | 81683 | 40233 |  | 121916 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property and equipment and intangible assets | 54448 | 5453 |  | 59901 |
| **November 27, 2021:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $4432508 | $1858830 | $(62458) | $6228880 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 1233237 | 101146 |  | 1334383 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(2)</sup> | 125931 | 28862 |  | 154793 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property and equipment and intangible assets | 44501 | 4954 |  | 49455 |
| **Thirty-Nine Week Period Ended** |  |  |  |  |
| &nbsp;&nbsp;**November 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $12989379 | $5180031 | $(170413) | $17998997 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 3239672 | 315304 |  | 3554976 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(2)</sup> | 186849 | 113746 |  | 300595 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property and equipment and intangible assets | 179342 | 18158 |  | 197500 |
| &nbsp;&nbsp;**November 27, 2021:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $13061408 | $5629325 | $(187868) | $18502865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 3543533 | 321649 |  | 3865182 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(2)</sup> | 290214 | 109616 |  | 399830 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions to property and equipment and intangible assets | 155942 | 13348 |  | 169290 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

&nbsp;&nbsp;&nbsp;&nbsp;(2) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" in Management's Discussion and Analysis of Financial Condition and Results for additional details.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The following is a reconciliation of net loss to Adjusted EBITDA for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **November 26,**<br>**2022**<br>**(13 weeks)** | **November 27,**<br>**2021**<br>**(13 weeks)** | **November 26,**<br>**2022**<br>**(39 weeks)** | **November 27,**<br>**2021**<br>**(39 weeks)** |
| Net loss | $(67144) | $(36058) | $(508625) | $(149416) |
| &nbsp;&nbsp;Interest expense | 57416 | 47794 | 158068 | 145507 |
| &nbsp;&nbsp;Income tax (benefit) expense | (510) | (1175) | 14954 | 2915 |
| &nbsp;&nbsp;Depreciation and amortization  | 69496 | 72973 | 208133 | 222691 |
| &nbsp;&nbsp;LIFO charge | 15246 | 8886 | 25367 | 900 |
| &nbsp;&nbsp;Facility exit and impairment charges | 22539 | 47455 | 134955 | 67639 |
| &nbsp;&nbsp;Goodwill and intangible asset impairment charges |  |  | 252200 |  |
| (Gain) loss on debt modifications and retirements, net |  |  | (41312) | 3235 |
| &nbsp;&nbsp;Merger and Acquisition-related costs |  | 3642 |  | 12119 |
| &nbsp;&nbsp;Stock-based compensation expense | 566 | 217 | 8635 | 8820 |
| &nbsp;&nbsp;Restructuring-related costs | 26500 | 9657 | 61951 | 25173 |
| &nbsp;&nbsp;Inventory write-downs related to store closings | 3085 | 86 | 12134 | 1356 |
| &nbsp;&nbsp;Litigation and other contractual settlements | (2541) | 2000 | 35823 | 50212 |
| &nbsp;&nbsp;Gain on sale of assets, net | (3095) | (5899) | (61292) | (79) |
| &nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |  | 5346 |
| &nbsp;&nbsp;Other | 358 | (131) | (396) | 3412 |
| Adjusted EBITDA | $121916 | $154793 | $300595 | $399830 |

---

**16. Commitments, Contingencies and Guarantees**

***Legal Matters and Regulatory Proceedings***

The Company is regularly involved in a variety of legal matters including arbitration, litigation (and related settlement discussions), audits by counter parties under our contracts, and other claims, and is subject to regulatory proceedings including audits, inspections, inquiries, investigations, and similar actions by health care, insurance, pharmacy, tax and other governmental authorities arising in the ordinary course of its business, including, without limitation, the matters described below. Substantial damages are sought from the Company in virtually all of these matters. The Company records accruals for outstanding legal matters and applicable regulatory proceedings when it believes it is probable that a loss has been incurred, and the amount can be reasonably estimated. The Company evaluates on a quarterly basis, developments in legal matters and regulatory proceedings that could affect the amount of any existing accrual or that warrant an accrual. If a loss contingency is not both probable and estimable, the Company typically does not establish an accrued liability. With respect to the litigation and other legal proceedings described below, the Company is unable to estimate the amount or range of reasonably possible loss due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

None of the Company's accruals for outstanding legal matters or regulatory proceedings are currently material, individually or in the aggregate, to the Company's consolidated financial position. However, during the course of any proceeding, developments may result in the creation or an increase of an accrual that could be material. Additionally, unfavorable or unexpected outcomes in outstanding legal matters or regulatory proceedings could exceed any accrual and impact the Company's financial position. Further, even if the Company is successful in its legal proceedings, the Company may incur significant costs and expenses defending itself or others that it is required to indemnify, and such costs and expenses may not be subject to or may exceed reimbursement pursuant to any applicable insurance.

The Company's contingencies are subject to significant uncertainties, many of which are beyond the Company's control, including, among other factors: (i) the stage of any proceeding and delays in scheduling; (ii) whether class or collective action status is sought and the likelihood of a class being certified; (iii) the outcome of pending or potential appeals, motions and settlement discussions; (iv) the range and magnitude of potential damages, fines or penalties, which are often unspecified or indeterminate; (v) the impact of discovery on the matter; (vi) whether novel or unsettled legal theories are at issue or advanced; (vii) whether there are significant factual issues to be resolved including findings made by juries; (viii) the exercise of discretion in enforcement actions including in the case of certain government agency investigations, whether a *qui tam* lawsuit ("whistleblower" action) has been filed and whether the government agency makes a decision to intervene in the lawsuit following investigation; and/or (ix) changes in priorities following any change in political administration at the state or federal level.

*Employment Litigation.* 

The Company is currently a defendant in several lawsuits filed in courts in California that contain allegations regarding violations of the California Business and Professions Code, various California employment laws and regulations, industry wage orders, wage-and-hour laws, rules and regulations pertaining primarily to failure to pay overtime, failure to pay premiums for missed meals and rest periods, failure to provide accurate wage statements, and failure to reimburse business expenses (the "California Cases").

Some of the California Cases purport or may be determined to be class actions or representative actions under the California Private Attorneys General Act and seek substantial damages and penalties. In June 2021, the Company agreed to settle two of the California Cases in which the plaintiffs brought class-based claims alleging that they and all other similarly situated associates were not paid for time waiting for their bags to be checked. One set of cases involving store associates was settled for $9 million, the other involving distribution center associates was settled for $1.75 million, and both have concluded. On October 1, 2021, the Company agreed to settle for $12 million allegations made by a purported class of California store associates that it required such associates to purchase uniforms, and the matter has concluded. In August 2022, the Company agreed to settle a putative class action regarding reimbursement for cell phone and mileage expenses for shift supervisors and managers/assistant managers for $1.29 million, and a putative wage and hour class action brought on behalf of drivers and other ice cream plant associates for $0.8 million.

The Company has also reached an agreement in principle to resolve a putative employment collective and class action filed in federal court in New York, which raises similar allegations in addition to others about the payment frequency for certain employees (the "New York Case"). In December 2022, the parties reached an agreement in principle to resolve the individual plaintiff's claims as well as those of the class, resulting in the federal court issuing an order of judgment and a new matter filed in New York state court, which the parties have agreed to resolve for $6.45 million.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The Company has aggressively defended itself and challenged the merits of the lawsuits and, where applicable, allegations that the lawsuits should be certified as class or representative actions.

*Usual and Customary Litigation.*

The Company is named as a defendant in a number of lawsuits, including the cases below, that allege that the Company's retail stores overcharged for prescription drugs by not submitting the price available to members of the Rite Aid's Rx Savings Program as the pharmacy's usual and customary price, and related theories. The Company has aggressively defended against the allegations of these matters and continues to challenge their merit.

The Company is a defendant in a putative consumer class action lawsuit in the United States District Court for the Southern District of California captioned *Byron Stafford v. Rite Aid Corp*. A separate lawsuit, *Robert Josten v. Rite Aid Corp*., was consolidated with this lawsuit in November, 2019. The lawsuit contains allegations that (i) the Company was obligated to charge the plaintiffs' insurance companies its usual and customary prices for their prescription drugs; and (ii) the Company failed to do so because the prices it reported were not equal to or adjusted to account for the prices that Rite Aid offered to uninsured and underinsured customers through its Rx Savings Program. Prior stays pending mediation have now been lifted in these matters and another lawsuit raising usual and customary pricing allegations filed in the United States District Court for the Eastern District of Pennsylvania.

On February 6, 2019, Humana, Inc., filed a claim pursuant to a binding arbitration provision of the parties' agreement alleging that the Company improperly submitted various usual and customary overcharges by failing to report its Rx Savings Program prices as its usual and customary prices to Humana. An arbitration hearing was held in this matter in November 2021.

On April 22, 2022, the arbitrator issued an Opinion and Final Award against the Company for breach of contract awarding Humana $122.6 million, which includes $40.7 million in prejudgment interest (the "Arbitration Award"). The Company believes that the Arbitration Award contains a number of significant factual and legal errors. On June 20, 2022, the Company both opposed Humana's effort to confirm the Arbitration Award and petitioned the United States District Court for Western District of Kentucky for vacatur of the Arbitration Award, as is its right under the Federal Arbitration Act ("FAA"). As such, the Company has determined that it is not probable that a loss has occurred.

The FAA, as interpreted and applied by federal courts, permits vacatur when, among other things, an arbitrator's decision: (1) is irreconcilable with the terms of a contract between the parties; (2) rests on a plain legal error that manifests disregard for the law; or (3) incorporates a refusal to consider pertinent, material evidence. Similarly, the FAA, as interpreted and applied by federal courts, permits modification of an arbitrator's decision to correct an evident material miscalculation of figures. Although the Company cannot make any assurances of success in its efforts, it is the Company's view that the errors in the Arbitration Award support both vacatur and modification under the FAA, the effect of either of which could be to set aside the Arbitration Award or reduce or eliminate the damages provided for in the Arbitration Award.

Humana filed a petition in the District Court for the Western District of Kentucky to confirm the Arbitration Award and Rite Aid filed a motion for vacatur of the Arbitration Award on June 20, 2022. Briefing was completed on these matters on August 19, 2022. Rite Aid has requested a hearing on the matter.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

The Company is a defendant in two consolidated lawsuits pending in the United States District Court for the District of Minnesota filed in 2020 by various Blue Cross/Blue Shield plans that operate in eight different states (North Carolina, North Dakota, Alabama, Utah, Minnesota, Oregon, Washington and New Jersey) alleging that the Company improperly submitted various usual and customary overcharges by failing to report its Rx Savings Program pricing to several Pharmacy Benefit Managers with which Rite Aid and the insurers had independent contracts. The Company is also defending a lawsuit filed in Delaware state court in 2019 by multiple Centene entities alleging that the Company overcharged for prescriptions by improperly reporting usual and customary prices that did not include Rx Savings Program pricing. The Company is defending a similar lawsuit filed in 2022 by WellCare in Florida state court.

*Drug Utilization Review and Code 1 Litigation*

In June 2012, *qui tam* plaintiff, Loyd F. Schmuckley ("Relator") filed a complaint under seal against the Company alleging that it failed to comply with certain requirements of California's Medicaid program between 2007 and 2014. In June 2013, the Company was served with a Civil Investigative Demand ("CID") by the United States Attorney's Office for the Eastern District of California regarding (1) the Company's Drug Utilization Review and prescription dispensing protocol; and (2) the dispensing of drugs designated as "Code 1" by the State of California. Specifically, the Relator alleged that the Company did not perform special verification and documentation for certain medications known as "Code 1" drugs. While the complaint remained under seal, the United States Department of Justice conducted an extensive investigation and ultimately declined to intervene. Although numerous states declined to intervene, in September 2017, the State of California filed a complaint in intervention. The Company filed a motion to dismiss Relator's and the State of California Department of Justice's Bureau of Medical Fraud and Elder Abuse respective complaints in January 2018, the hearing was held on March 23, 2018. On September 5, 2018, the court issued an order denying the motion to dismiss. Substantial damages are sought from the Company in this matter. The Company has aggressively defended against the allegations of the lawsuit and continues to challenge their merit. No trial date has been set and as discovery continues, the parties have participated in and are expected to continue to participate in a mediation process.

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

*Controlled Substances Litigation, Audits and Investigations*

The Company, along with various other defendants, is named in multiple opioid-related lawsuits filed by counties, cities, municipalities, Native American tribes, hospitals, third-party payers, and others across the United States. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation ("JPML") consolidated and transferred more than a thousand federal opioid-related lawsuits that name the Company as a defendant to the multi-district litigation ("MDL") pending in the United States District Court for the Northern District of Ohio under *In re National Prescription Opiate Litigation* (Case No. 17-MD-2804). A significant number of similar cases that are not part of the MDL and name the Company as a defendant are also pending in state courts. On June 1, 2022, the JPML ordered that newly filed cases will no longer be transferred to the MDL. The plaintiffs in these opioid-related lawsuits generally allege claims that include public nuisance and negligence theories of liability resulting from the impacts of widespread opioid abuse against defendants along the pharmaceutical supply chain, including manufacturers, wholesale distributors, and retail pharmacies. At this stage of the proceedings, the Company is not able to predict the outcome of the opioid-related lawsuits in which it remains a defendant or estimate a potential range of loss regarding the lawsuits, and is aggressively defending itself against all relevant claims, and continues to challenge their merit. From time to time, some of these cases may be settled, dismissed or otherwise terminated, and additional such cases may be filed.

The Company also has received warrants, subpoenas, CIDs, and other requests for documents and information from, and is being investigated by, the federal and state governments regarding opioids and other controlled substances. The Company has been cooperating with and responding to these investigatory inquiries.

On December 13, 2022, a qui tam complaint filed by three former Rite Aid pharmacy personnel (Andrew White, Mark Rosenberg, and Ann Wegelin) ("*qui tam* Relators") was unsealed by the federal District Court for the Northern District of Ohio in an order that also directed the United States to file within 90 days a complaint intervening or partially intervening in the Second Amended Complaint (the "Complaint"). The Complaint has been joined by California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, Nevada, New Hampshire, New Jersey, New York, North Carolina, Oklahoma, Rhode Island, Tennessee, Texas, Vermont, Virginia, Washington and the District of Columbia. The order to unseal the Complaint followed the United States' November 18, 2022 Notice of Intervention In Part. The original *qui tam* complaint was filed under seal in October 2019, with the complaint amended under seal by the *qui tam* Relators in January 2020 and further amended under seal in January 2021. The Complaint alleges violations of federal and state false claims acts related to the dispensing of controlled substances, namely opioids, and that Rite Aid failed to implement effective controls to prevent the filling or inappropriate prescriptions of opioids, or to otherwise detect diversion and abuse of controlled substances. The Complaint seeks injunctive relief ordering Rite Aid to cease and desist from the complained-of practices, and further seeks both damages and civil penalties under federal and state statues for each allegedly false claim arising in relation to Medicaid, Medicare, Federal employee plans and Tricare, among other government programs.

In April 2019, the Company initiated a coverage action styled *Rite Aid Corporation et al. v. ACE American Ins. Co. et al*. Through this action, the Company is seeking the recovery of defense costs and settlement and/or judgment costs that may be paid for the opioid-related lawsuits. The action seeks declaratory relief with respect to the obligations of the insurers under the policies at issue in the action and asserts claims for breach of contract and statutory remedies against one of these insurers. Although the trial court determined on the Company's motion for partial summary judgment that this insurer was obligated to reimburse the Company for its defense costs, on January 10, 2022, the Delaware Supreme Court reversed the trial court's order and ruled that the insurer had no duty to defend the first MDL

[**Table of Contents**](#TOC)

**RITE AID CORPORATION AND SUBSIDIARIES**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**For the Thirteen and Thirty-Nine Week Periods Ended November 26, 2022 and November 27, 2021**

**(Dollars and share information in thousands, except per share amounts)**

**(unaudited)**

suits set for trial based on the specific allegations at issue in those cases. The matter has been remanded to the lower court for further proceedings.

*Miscellaneous Litigation and Investigations.*

In March 2022, the Company became aware that the U.S. Securities and Exchange Commission ("SEC") had concluded its investigation of trading in the Company's securities that occurred in or around January 2017. The Company cooperated in the investigation and was not alleged to have violated the federal securities laws or otherwise engaged in wrongdoing. The Company has received a CID and requests for information from the Federal Trade Commission with respect to consumer protection laws and CIDs from the Department of Justice related to the Medicare Part D plan sponsored by a subsidiary of the Company. The Company is also aggressively defending a lawsuit asserting numerous claims based on allegations, the merits of which the Company challenges, surrounding the Company's use of a certain font including in the Company's rebranded logo.

The Company is defending a putative shareholder class action currently captioned *Page v. Rite Aid Corporation et al.*, filed in the United States District Court for the Eastern District of Pennsylvania. The matter names Rite Aid Corporation and certain executives individually as defendants and raises claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 related to alleged misstatements and omissions concerning the growth of Elixir's pharmacy benefit management ("PBM") services businesses. The matter remains in early stages, but the Company intends to aggressively defend against the allegations and challenge their merit.

**17. Supplementary Cash Flow Data**

---

| | | |
|:---|:---|:---|
|  | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26, 2022** | **November 27, 2021** |
| Cash paid for interest | $118842 | $102633 |
| Cash (refunds) payments for income taxes, net | $(6805) | $3521 |
| Equipment financed under capital leases | $2383 | $1698 |
| Gross borrowings from revolver | $2597000 | $4191000 |
| Gross repayments to revolver | $1956000 | $3891000 |

---

Significant components of cash provided by Other Liabilities of $9,537 for the thirty-nine week period ended November 26, 2022 include cash provided from an increase in accrued interest, partially offset by a decrease in benefits and other operating expense related accruals.

[**Table of Contents**](#TOC)

**ITEM 2. Management's Discussion and Analysis of Financial Condition and Results** 

**Overview**

We are a healthcare company with a retail footprint, providing our customers and communities with a high level of care and service through various programs we offer through our two reportable business segments, our Retail Pharmacy segment and our Pharmacy Services segment. We accomplish our goal of delivering comprehensive care to our customers through our retail drugstores and our PBM, Elixir. We also offer fully integrated mail-order and specialty pharmacy services through Elixir Pharmacy. Additionally, through Elixir Insurance ("EI"), Elixir also serves seniors enrolled in Medicare Part D. When combined with our retail platform, this comprehensive suite of services allows us to provide value and choice to customers, patients and payors and allows us to compete in today's evolving healthcare marketplace.

*Retail Pharmacy Segment*

Our Retail Pharmacy segment sells brand and generic prescription drugs and provides various other pharmacy services, as well as an assortment of front-end products including health and beauty aids, personal care products, seasonal merchandise, and a large private brand product line. Our Retail Pharmacy segment generates the majority of its revenue through the sale of prescription drugs and front-end products at our over 2,300 retail pharmacy locations across 17 states and through our e-commerce platform available at *www.riteaid.com*. We replenish our retail stores through a combination of direct store delivery of pharmaceutical products facilitated through our pharmaceutical Purchasing and Delivery Agreement with McKesson, and the majority of our front-end products through our network of distribution centers.

*Pharmacy Services Segment*

Our Pharmacy Services segment provides a fully integrated suite of PBM offerings including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication and pharmacy discount programs. Elixir also provides prescription discount programs and Medicare Part D insurance offerings for individuals and groups. Elixir provides services to various clients across its different lines of business, including major health plans, commercial employers, labor groups and state and local governments, representing approximately 2.3 million covered lives, including approximately 0.7 million covered lives through our Medicare Part D insurance offerings. Elixir continues to focus its efforts and offerings to its target market of small to mid-market employers, labor unions and regional health plans, including provider-led health plans and government sponsored Medicaid and Medicare plans.

**Restructuring**

Beginning in Fiscal 2019, we initiated a series of restructuring plans designed to reorganize our executive management team, reduce managerial layers, and consolidate roles. In March 2020, we announced the details of our RxEvolution strategy, which includes building tools to work with regional health plans to improve patient health outcomes, rationalizing SKU's in our front-end offering to free up working capital and update our merchandise assortment, assessing our pricing and promotional strategy, rebranding our retail pharmacy and pharmacy services business, launching our Store of the Future format and further reducing SG&A and headcount, including integrating certain back office functions in the Pharmacy Services segment both within the segment and across the enterprise. Other strategic initiatives include the expansion of our digital business, replacing and updating the Company's financial systems to improve efficiency, and movement to a common client platform at Elixir. In April 2022, we announced further strategic initiatives to reduce costs through the closure of unprofitable stores, reduce corporate administration expenses, improve efficiencies in worked payroll and other store labor costs, engage in a comprehensive review of purchasing and other business processes in both the Retail Pharmacy and Pharmacy Services segments in order to identify areas of opportunity, as well as expense reductions at our Pharmacy Services segment. These and future restructuring activities are expected to provide future growth and expense efficiency benefits. There can be no assurance

[**Table of Contents**](#TOC)

that our current and future restructuring charges will achieve the cost savings and remerchandising benefits in the amounts or time anticipated.

**Impact of COVID-19** 

In March 2020, the outbreak of COVID-19 caused by a novel strain of the coronavirus was recognized as a pandemic by the World Health Organization. The COVID-19 pandemic has severely impacted the economies of the United States and other countries around the world.

The COVID-19 pandemic had a significant impact on our operating results for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021 and will continue to have an impact on several factors underlying our operating results and liquidity in fiscal 2023. Those factors include the number of individuals that receive a COVID-19 vaccine or booster; demand for COVID-19 testing; the timing and extent to which elective procedures return to pre-pandemic levels; the demand for flu and other immunizations and the length and severity of the upcoming cough, cold and flu season.

**Overview of Financial Results** 

Our net loss for the thirteen week period ended November 26, 2022 was $67.1 million or $1.23 per basic and diluted share compared to a net loss of $36.1 million or $0.67 per basic and diluted share for the thirteen week period ended November 27, 2021. Our net loss for the thirty-nine week period ended November 26, 2022 was $508.6 million or $9.32 per basic and diluted share compared to a net loss of $149.4 million or $2.77 per basic and diluted share for the thirty-nine week period ended November 27, 2021.

The increase in net loss for the thirteen week period ended November 26, 2022 is due primarily to a decrease in Adjusted EBITDA, an increase in interest expense and an increase in restructuring charges. These items were partially offset by a reduction in facility exit and impairment charges.

The increase in net loss for the thirty-nine week period ended November 26, 2022 was due primarily to a second quarter charge of $252.2 million, or $4.62 per share, for the impairment of goodwill related to the Pharmacy Services segment. Net loss was also impacted by decreased Adjusted EBITDA, higher facility exit and impairment charges driven by the Company's previously announced store closures, and higher interest expense. These items are partially offset by a gain on our repurchase of certain bonds at a discount, a gain on sale of assets resulting primarily from sale leasebacks of two distribution centers and script file sales resulting from the store closures.

Our Adjusted EBITDA for the thirteen and thirty-nine week periods ended November 26, 2022 was $121.9 million or 2.0% of revenues and $300.6 million or 1.7% of revenues, respectively, compared to $154.8 million or 2.5% of revenues and $399.8 million or 2.2% of revenues, respectively, for the thirteen and thirty-nine week periods ended November 27, 2021.

The decrease in Adjusted EBITDA for the thirteen week period ended November 26, 2022 was due to a decline in the Retail Pharmacy segment, partially offset by an increase in the Pharmacy Services segment. Adjusted EBITDA decreased $44.2 million in the Retail Pharmacy segment due primarily to a decrease in gross profit, partially offset by a decrease in selling, general and administrative expenses ("SG&A"). Adjusted EBITDA in the Pharmacy Services segment increased $11.4 million due primarily to an increase in gross profit resulting from improved procurement economics and reductions in SG&A expense, partially offset by the decline in revenues associated with lost clients.

The decrease in Adjusted EBITDA for the thirty-nine week period ended November 26, 2022 was due to a decline in the Retail Pharmacy segment, partially offset by an increase in the Pharmacy Services segment. Adjusted EBITDA decreased $103.4 million in the Retail Pharmacy segment due primarily to a decrease in gross profit, partially offset by a decrease in SG&A of $166.6 million. Adjusted EBITDA in the Pharmacy Services segment increased $4.1 million due primarily to reductions in SG&A expense, partially offset by a decrease in gross profit.

[**Table of Contents**](#TOC)

Please see the sections entitled "Segment Analysis" and "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" below for additional details.

**Consolidated Results of Operations**

*Revenues and Other Operating Data*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands except per share amounts)** | **(dollars in thousands except per share amounts)** | **(dollars in thousands except per share amounts)** | **(dollars in thousands except per share amounts)** |
| Revenues<sup>(a)</sup> | $6083346 | $6228880 | $17998997 | $18502865 |
| Revenue (decline) growth | (2.3)% | 1.8% | (2.7)% | 2.1% |
| Net loss | $(67144) | $(36058) | $(508625) | $(149416) |
| Net loss per diluted share | $(1.23) | $(0.67) | $(9.32) | $(2.77) |
| Adjusted EBITDA<sup>(b)</sup> | $121916 | $154793 | $300595 | $399830 |
| Adjusted Net (Loss) Income<sup>(b)</sup> | $(7930) | $8164 | $(75418) | $7132 |
| Adjusted Net (Loss) Income per Diluted Share<sup>(b)</sup> | $(0.14) | $0.15 | $(1.38) | $0.13 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) Revenues for the thirteen and thirty-nine week periods ended November 26, 2022 exclude $55,819 and $170,413 , respectively, of inter-segment activity that is eliminated in consolidation. Revenues for the thirteen and thirty-nine week periods ended November 27, 2021 exclude $62,458 and $187,868 , respectively, of inter-segment activity that is eliminated in consolidation.

&nbsp;&nbsp;&nbsp;&nbsp;(b) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" for additional details.

*Revenues*

Revenues decreased 2.3% and 2.7% for the thirteen and thirty-nine week periods ended November 26, 2022, compared to an increase of 1.8% and 2.1% for the thirteen and thirty-nine week periods ended November 27, 2021. Revenues for the thirteen week period ended November 26, 2022 were impacted by a $20.3 million decrease in Retail Pharmacy segment revenues and a $131.9 million decrease in Pharmacy Services segment revenues. Revenues for the thirty-nine week period ended November 26, 2022 were impacted by a $72.0 million decrease in Retail Pharmacy segment revenues and a $449.3 million decrease in Pharmacy Services segment revenues.

Please see the section entitled "Segment Analysis" below for additional details regarding revenues.

[**Table of Contents**](#TOC)

*Costs and Expenses*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Cost of revenues<sup>(a)</sup> | $4879594 | $4894497 | $14444021 | $14637683 |
| Gross profit | 1203752 | 1334383 | 3554976 | 3865182 |
| Gross margin | 19.8% | 21.4% | 19.8% | 20.9% |
| Selling, general and administrative expenses | $1194546 | $1276920 | $3606028 | $3790035 |
| Selling, general and administrative expenses as a percentage of revenues | 19.6% | 20.5% | 20.0% | 20.5% |
| Facility exit and impairment charges | 22539 | 47455 | 134955 | 67639 |
| Goodwill and intangible asset impairment charges |  |  | 252200 |  |
| Interest expense | 57416 | 47794 | 158068 | 145507 |
| (Gain) loss on debt modifications and retirements, net |  |  | (41312) | 3235 |
| Gain on sale of assets, net | (3095) | (5899) | (61292) | (79) |
| Loss on Bartell acquisition |  | 5346 |  | 5346 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Cost of revenues for the thirteen and thirty-nine week periods ended November 26, 2022 exclude $55,819 and $170,413 , respectively, of inter-segment activity that is eliminated in consolidation. Cost of revenues for the thirteen and thirty-nine week periods ended November 27, 2021 exclude $62,458 and $187,868 , respectively, of inter-segment activity that is eliminated in consolidation.

*Gross Profit and Cost of Revenues*

Gross profit decreased by $130.6 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021. Gross profit decreased by $310.2 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021. Gross profit for the thirteen week period ended November 26, 2022 includes a decrease of $134.0 million in our Retail Pharmacy segment, partially offset by an increase of $3.3 million in our Pharmacy Services segment. Gross profit for the thirty-nine week period ended November 26, 2022 includes a decrease of $303.9 million in our Retail Pharmacy segment and a decrease of $6.3 million in our Pharmacy Services segment. Gross margin was 19.8% for the thirteen week period ended November 26, 2022 compared to 21.4% for the thirteen week period ended November 27, 2021. Gross margin was 19.8% for the thirty-nine week period ended November 26, 2022 compared to 20.9% for the thirty-nine week period ended November 27, 2021. Please see the section entitled "Segment Analysis" for a more detailed description of gross profit and gross margin results by segment.

*Selling, General and Administrative Expenses*

SG&A decreased by $82.4 million for the thirteen week period ended November 26, 2022, compared to the thirteen week period ended November 27, 2021. The decrease in SG&A for the thirteen week period ended November 26, 2022 includes a decrease of $67.2 million relating to our Retail Pharmacy segment and a decrease of $15.2 million

[**Table of Contents**](#TOC)

relating to our Pharmacy Services segment. SG&A decreased by $184.0 million for the thirty-nine week period ended November 26, 2022, compared to the thirty-nine week period ended November 27, 2021. The decrease in SG&A for the thirty-nine week period ended November 26, 2022 includes a decrease of $168.6 million relating to our Retail Pharmacy segment and a decrease of $15.4 million relating to our Pharmacy Services segment. Please see the section entitled "Segment Analysis" below for additional details regarding SG&A.

*Facility Exit and Impairment Charges*

Facility exit and impairment charges consist of amounts as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week** | **Thirteen Week** | **Thirty-Nine Week** | **Thirty-Nine Week** |
|  | **Period Ended** | **Period Ended** | **Period Ended** | **Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| Impairment charges  | $7728 | $40323 | $77502 | $51372 |
| Facility exit charges  | 14811 | 7132 | 57453 | 16267 |
|  | $22539 | $47455 | $134955 | $67639 |

---

Please refer to "Management's Discussion and Analysis of Financial Condition and Results—Facility Exit and Impairment Charges" included in our Fiscal 2022 10-K for a detailed description of our impairment and lease termination methodology.

*Interest Expense*

Interest expense was $57.4 million and $158.1 million for the thirteen and thirty-nine week periods ended November 26, 2022, respectively, compared to $47.8 million and $145.5 million for the thirteen and thirty-nine week periods ended November 27, 2021, respectively. The weighted average interest rate on our indebtedness for the thirty-nine week periods ended November 26, 2022 and November 27, 2021 was 6.7% and 4.3%, respectively. We have variable interest rate debt and in the current rising interest rate environment, our interest expense may increase.

*Income Taxes*

We recorded an income tax benefit of $0.5 million and $1.2 million for the thirteen week periods ended November 26, 2022 and November 27, 2021, respectively. We recorded income tax expense of $15.0 million and $2.9 million for the thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. The effective tax rate for the thirteen week periods ended November 26, 2022 and November 27, 2021 was 0.8% and 3.2%, respectively. The effective tax rate for the thirty-nine week periods ended November 26, 2022 and November 27, 2021 was (3.0)% and (2.0)%, respectively. The effective tax rate for the thirteen and thirty-nine week periods ended November 26, 2022 was net of an adjustment of (19.5)% and 46.5%, respectively, to adjust the valuation allowance against deferred tax assets. The effective tax rate for the thirty-nine week period ended November 26, 2022 was primarily impacted by a Pennsylvania law change that reduced the statutory corporate net income tax rate, causing a reduction to the valuation allowance of $380.5 million. The effective tax rate for the thirteen and thirty-nine week periods ended November 27, 2021 was net of an adjustment of (18.5)% and (21.4)%, respectively, to adjust the valuation allowance against deferred tax assets.

We recognize tax liabilities in accordance with the guidance for uncertain tax positions and management adjusts these liabilities with changes in judgment as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from the current estimate of the tax liabilities.

We believe that it is reasonably possible that a decrease of up to $25.1 million in unrecognized tax benefits related to state exposures may be necessary in the next twelve months; however, management does not expect the change to have a material impact on the results of operations or the financial position of the Company.

We regularly evaluate valuation allowances established for deferred tax assets for which future realization is uncertain. We will continue to monitor all available evidence related to the net deferred tax assets that may change the

[**Table of Contents**](#TOC)

most recent assessment, including events that have occurred or are anticipated to occur. We continue to maintain a valuation allowance against net deferred tax assets of $1,593.2 million and $1,822.7 million, which relates to federal and state deferred tax assets that may not be realized based on our future projections of taxable income at November 26, 2022 and February 26, 2022, respectively.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implemented a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases, and several tax incentives to promote clean energy. Based on our current analysis of the provisions, we do not believe that this legislation will have a material impact on our financial statements.

**Segment Analysis**

We evaluate the Retail Pharmacy and Pharmacy Services segments' performance based on revenue, gross profit, and Adjusted EBITDA. The following is a reconciliation of our segments to the condensed consolidated financial statements:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Retail**<br>**Pharmacy** | **Pharmacy**<br>**Services** | **Intersegment**<br>**Eliminations**<sup>(1)</sup> | <br>**Consolidated** |
| **Thirteen Week Period Ended** |  |  |  |  |
| &nbsp;&nbsp;**November 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $4412232 | $1726933 | $(55819) | $6083346 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 1099279 | 104473 |  | 1203752 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(\*)</sup> | 81683 | 40233 |  | 121916 |
| &nbsp;&nbsp;**November 27, 2021:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $4432508 | $1858830 | $(62458) | $6228880 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 1233237 | 101146 |  | 1334383 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(\*)</sup> | 125931 | 28862 |  | 154793 |
| **Thirty-Nine Week Period Ended** |  |  |  |  |
| &nbsp;&nbsp;**November 26, 2022:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $12989379 | $5180031 | $(170413) | $17998997 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 3239672 | 315304 |  | 3554976 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(\*)</sup> | 186849 | 113746 |  | 300595 |
| &nbsp;&nbsp;**November 27, 2021:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Revenues | $13061408 | $5629325 | $(187868) | $18502865 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross Profit | 3543533 | 321649 |  | 3865182 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA<sup>(\*)</sup> | 290214 | 109616 |  | 399830 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(\*) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" for additional details.

[**Table of Contents**](#TOC)

**Retail Pharmacy Segment Results of Operations**

*Revenues and Other Operating Data*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Revenues | $4412232 | $4432508 | $12989379 | $13061408 |
| Revenue (decline) growth | (0.5)% | 7.9% | (0.6)% | 6.6% |
| Same store sales growth | 7.5% | 4.4% | 5.9% | 3.2% |
| Pharmacy sales growth | 0.7% | 10.4% | 1.2% | 11.7% |
| Same store prescription count growth, adjusted to 30-day equivalents | 4.4% | 7.9% | 2.8% | 8.7% |
| Same store pharmacy sales growth | 9.5% | 5.9% | 8.0% | 7.0% |
| Pharmacy sales as a % of total retail sales | 72.0% | 71.1% | 71.2% | 69.9% |
| Front-end sales (decline) growth | (3.4)% | 2.2% | (4.6)% | (3.3)% |
| Same store front-end sales growth (decline) | 2.2% | 0.4% | 0.5% | (5.2)% |
| Front-end sales as a % of total retail sales | 28.0% | 28.9% | 28.8% | 30.1% |
| Adjusted EBITDA<sup>(\*)</sup> | $81683 | $125931 | $186849 | $290214 |
| Store data: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stores (beginning of period) | 2352 | 2501 | 2450 | 2510 |
| &nbsp;&nbsp;&nbsp;&nbsp;New stores | 1 | 1 | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Store acquisitions |  |  |  | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Closed stores | (29) | (14) | (127) | (25) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stores (end of period) | 2324 | 2488 | 2324 | 2488 |
| &nbsp;&nbsp;&nbsp;&nbsp;Relocated stores |  |  | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Remodeled and expanded stores | 8 | 3 | 21 | 9 |

---

(\*) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" for additional details.

*Revenues*

Revenues decreased 0.5% for the thirteen week period ended November 26, 2022 compared to an increase of 7.9% for the thirteen week period ended November 27, 2021. The decrease in revenues for the thirteen week period ended November 26, 2022 was driven by a reduction in COVID vaccine and testing revenue as well as store closures, partially offset by an increase in both acute and maintenance prescriptions.

Pharmacy same store sales increased by 9.5% for the thirteen week period ended November 26, 2022 compared to an increase of 5.9% for the thirteen week period ended November 27, 2021. The increase in pharmacy same store sales is due to the increase in same store prescription count. Same store prescription count, adjusted to 30-day equivalents, increased 4.4% for the thirteen week period ended November 26, 2022 driven primarily by an increase in non-COVID same store prescriptions of 3.6%, with same store maintenance prescriptions increasing 2.1% and other same store acute prescriptions increasing 8.0%.

Front-end same store sales increased 2.2% during the thirteen week period ended November 26, 2022 compared to an increase of 0.4% during the thirteen week period ended November 27, 2021. Front-end same store sales, excluding tobacco products, increased 2.7%. Front-end same store sales were driven by increases in health, consumable and beauty categories, partially offset by decreases in alcohol and general merchandise.

Revenues decreased 0.6% for the thirty-nine weeks ended November 26, 2022 compared to an increase of 6.6% for the thirty-nine weeks ended November 27, 2021. The decrease in revenues for the thirty-nine week period ended November 26, 2022 was driven by a reduction in COVID vaccine and testing revenue as well as store closures, partially offset by an increase in non-COVID prescriptions.

[**Table of Contents**](#TOC)

Pharmacy same store sales increased by 8.0% for the thirty-nine week period ended November 26, 2022 compared to an increase of 7.0% in the thirty-nine week period ended November 27, 2021. The increase in pharmacy same store sales is due to the increase in same store prescription count. Same store prescription count, adjusted to 30-day equivalents, increased 2.8% for the thirty-nine week period ended November 26, 2022 driven primarily by an increase in non-COVID same store prescriptions of 3.1%, with same store maintenance prescriptions increasing 1.5% and other same store acute prescriptions increasing 8.3%.

Front-end same store sales increased 0.5% during the thirty-nine week period ended November 26, 2022 compared to a decrease of 5.2% during the thirty-nine week period ended November 27, 2021. Front-end same store sales, excluding tobacco products, increased 1.0%. Front-end same store sales were driven by increases in health and consumable products, partially offset by decreases in alcohol sales.

We include in same store sales all stores that have been open at least one year. Relocated and acquired stores are not included in same store sales until one year has lapsed.

*Costs and Expenses*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Cost of revenues | $3312953 | $3199271 | $9749707 | $9517875 |
| Gross profit | 1099279 | 1233237 | 3239672 | 3543533 |
| Gross margin | 24.9% | 27.8% | 24.9% | 27.1% |
| FIFO gross profit<sup>(\*)</sup> | 1114525 | 1242123 | 3265039 | 3544433 |
| FIFO gross margin<sup>(\*)</sup> | 25.3% | 28.0% | 25.1% | 27.1% |
| Selling, general and administrative expenses | $1118792 | $1185974 | 3336781 | 3505365 |
| Selling, general and administrative expenses as a percentage of revenues | 25.4% | 26.8% | 25.7% | 26.8% |

---

(\*) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" for additional details.

*Gross Profit and Cost of Revenues*

Gross profit decreased $134.0 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021. Gross profit decreased $303.9 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021. The decrease in gross profit for the thirteen and thirty-nine week periods ended November 26, 2022 was driven by the decline in COVID vaccinations and testing, a higher LIFO charge and increased shrink expense, partially offset by the increase in prescriptions filled.

Gross margin was 24.9% of sales for the thirteen week period ended November 26, 2022 compared to 27.8% of sales for the thirteen week period ended November 27, 2021. Gross margin was 24.9% of sales for the thirty-nine week period ended November 26, 2022 compared to 27.1% of sales for the thirty-nine week period ended November 27, 2021. The decline in gross margin as a percentage of revenues for the thirteen and thirty-nine week periods ended November 26, 2022 is due primarily to the reduction in COVID vaccinations and testing.

We use the last-in, first-out ("LIFO") method of inventory valuation, which is estimated on a quarterly basis and is finalized at year end when inflation rates and inventory levels are final. Therefore, LIFO costs for interim period financial statements are estimated. LIFO charges were $15.2 million and $25.4 million for the thirteen and thirty-nine week periods ended November 26, 2022, respectively, compared to LIFO charges of $8.9 million and $0.9 million for the thirteen and thirty-nine week periods ended November 27, 2021, respectively. The higher LIFO charges in the thirteen and thirty-nine week periods ended November 26, 2022 were mostly due to higher anticipated front-end inflation in fiscal 2023 than in fiscal 2022.

[**Table of Contents**](#TOC)

*Selling, General and Administrative Expenses*

SG&A expenses decreased $67.2 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021. SG&A expenses decreased $168.6 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021. The decrease in SG&A expenses for the thirteen and thirty-nine week periods ended November 26, 2022 is due primarily to lower payroll, occupancy, and other operating costs due to store closures and cost control initiatives.

SG&A expenses as a percentage of revenues for the thirteen week period ended November 26, 2022 was 25.4% compared to 26.8% for the thirteen week period ended November 27, 2021. SG&A expenses as a percentage of revenues for the thirty-nine week period ended November 26, 2022 was 25.7% compared to 26.8% for the thirty-nine week period ended November 27, 2021. The decrease in SG&A expenses as a percentage of revenues for the thirteen and thirty-nine week periods ended November 26, 2022 is due primarily to the items noted above.

**Pharmacy Services Segment Results of Operations**

*Revenues and Other Operating Data*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Revenues | $1726933 | $1858830 | $5180031 | $5629325 |
| Revenue decline | (7.1)% | (10.8)% | (8.0)% | (7.7)% |
| Adjusted EBITDA<sup>(\*)</sup> | $40233 | $28862 | $113746 | $109616 |

---

(\*) See "Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures" for additional details.

*Revenues*

Revenues decreased $131.9 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021. Revenues decreased $449.3 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021. The decrease in revenues was primarily the result of a planned decrease in EI membership and a previously announced client loss due to industry consolidation, partially offset by increased utilization of higher cost drugs.

The Inflation Reduction Act of 2022 contains several provisions affecting Medicare, which will take effect over various periods of time from 2023 to 2029. Based on our current analysis of the provisions, we do not believe that this legislation will have a material impact on our financial statements.

[**Table of Contents**](#TOC)

*Costs and Expenses*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Cost of revenues | $1622460 | $1757684 | $4864727 | $5307676 |
| Gross profit | 104473 | 101146 | 315304 | 321649 |
| Gross margin | 6.1% | 5.4% | 6.1% | 5.7% |
| Selling, general and administrative expenses | $75754 | $90946 | 269247 | 284670 |
| Selling, general and administrative expenses as a percentage of revenues | 4.4% | 4.9% | 5.2% | 5.1% |

---

*Gross Profit and Cost of Revenues*

Gross profit increased $3.3 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021. The increase in gross profit is primarily due to improved procurement economics, partially offset by the decline in revenues associated with lost clients, as mentioned above.

Gross margin was 6.1% of sales for the thirteen week period ended November 26, 2022 compared to 5.4% of sales for the thirteen week period ended November 27, 2021. The increase in gross margin is due primarily to the items noted above.

Gross profit decreased $6.3 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021. The decrease in gross profit is primarily due to the decline in revenues associated with lost clients, as mentioned above, partially offset by improved procurement economics.

Gross margin was 6.1% of sales for the thirty-nine week period ended November 26, 2022 compared to 5.7% of sales for the thirty-nine week period ended November 27, 2021. The increase in gross margin is due primarily to improved procurement economics.

*Selling, General and Administrative Expenses*

SG&A expenses decreased $15.2 million for the thirteen week period ended November 26, 2022 compared to the thirteen week period ended November 27, 2021 due primarily to decreased litigation and other contractual settlements, as well as further consolidation of administrative functions. SG&A expenses as a percentage of revenue was 4.4% for the for the thirteen week period ended November 26, 2022 compared to 4.9% for the thirteen week period ended November 27, 2021. The decrease in the thirteen week period SG&A expenses as a percentage of revenues is due primarily to the items noted above.

SG&A expenses decreased $15.4 million for the thirty-nine week period ended November 26, 2022 compared to the thirty-nine week period ended November 27, 2021 due primarily to further consolidation of administrative functions. SG&A expenses as a percentage of revenue was 5.2% for the thirty-nine week period ended November 26, 2022 compared to 5.1% for the thirty-nine week period ended November 27, 2021. The increase in the thirty-nine week period SG&A expenses as a percentage of revenues is due primarily to the loss of sales volume.

**Liquidity and Capital Resources**

*General*

We have two primary sources of liquidity: (i) cash provided by operating activities and (ii) borrowings under our revolving credit facility. Our principal uses of cash are to provide working capital for operations, to service our obligations to pay interest and principal on debt and to fund capital expenditures. Total liquidity as of November 26, 2022 was $1,320.6 million, which consisted of revolver borrowing capacity of $1,274.1 million and invested cash of

[**Table of Contents**](#TOC)

$46.5 million. Our revolver borrowing capacity increased $100.0 million upon entry into the Currently Effective Senior Secured Revolving Credit Facility, as further described below.

*Credit Facilities*

On December 20, 2018, we entered into a senior secured credit agreement (as amended by the First Amendment to Credit Agreement, dated as of January 6, 2020, the "Credit Agreement"; and the Credit Agreement, as further amended by the Second Amendment (as defined below), the "Amended Credit Agreement"), which Credit Agreement provided for facilities consisting of a $2.7 billion senior secured asset-based revolving credit facility ("Initial Senior Secured Revolving Credit Facility") and a $450.0 million "first-in, last-out" senior secured term loan facility ("Initial Senior Secured Term Loan" and together with the Initial Senior Secured Revolving Credit Facility, collectively, the "Initial Facilities"). In December 2018, we used proceeds from the Initial Facilities to refinance our prior $2.7 billion existing credit agreement.

On August 20, 2021, we entered into the Second Amendment to Credit Agreement (the "Second Amendment"), which, among other things, amended the Credit Agreement to provide for a $2.8 billion senior secured asset-based revolving credit facility ("Senior Secured Revolving Credit Facility") and a $350.0 million "first-in, last-out" senior secured term loan facility ("Senior Secured Term Loan" and together with the Senior Secured Revolving Credit Facility, collectively, the "Amended Facilities"). The Amended Facilities extended our debt maturity profile and provided additional liquidity. Borrowings under the Senior Secured Revolving Credit Facility bore interest at a rate per annum equal to, at our option, (x) a base rate (determined in a customary manner) plus a margin of between 0.25% to 0.75% or (y) an adjusted LIBOR rate (determined in a customary manner) plus a margin of between 1.25% and 1.75%, in each case based upon the Average ABL Availability (as defined in the Amended Credit Agreement). Borrowings under the Senior Secured Term Loan bore interest at a rate per annum equal to, at our option, (x) a base rate (determined in a customary manner) plus a margin of 1.75% or (y) an adjusted LIBOR rate (determined in a customary manner) plus a margin of 2.75%. We are required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Senior Secured Revolving Credit Facility, depending on Average ABL Availability (as defined in the Amended Credit Agreement). The Amended Facilities are scheduled to mature on August 20, 2026 (subject to a springing maturity if certain of our existing secured notes are not refinanced or repaid prior to the date that is 91 days prior to the stated maturity thereof).

Our borrowing capacity under the Senior Secured Revolving Credit Facility was based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. At November 26, 2022, we had $1,700.0 million of borrowings outstanding under the Amended Facilities and had letters of credit outstanding under the Senior Secured Revolving Credit Facility in a face amount of $175.9 million, which resulted in remaining borrowing capacity under the Senior Secured Revolving Credit Facility of $1,274.1 million. If at any time the total credit exposure outstanding under the Senior Secured Revolving Credit Facility exceeded the borrowing base, we would be required to repay amounts outstanding to eliminate such shortfall.

The Amended Credit Agreement restricted us and all of our subsidiaries, including the subsidiaries that guaranteed our obligations under the Amended Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the "Subsidiary Guarantors") from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in our store and lockbox deposit accounts and cash necessary to cover our current liabilities). The Amended Credit Agreement also stated that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default existed under the Amended Facilities or (ii) the sum of our borrowing capacity under our Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account was less than or equal to $275.0 million for three consecutive business days or less than or equal to $200.0 million on any day (a "cash sweep period"), the funds in our deposit accounts would be swept to a concentration account with the senior collateral agent and would be applied first to repay outstanding revolving loans under the Amended Facilities, and then held as collateral for the senior obligations until such cash sweep period was rescinded pursuant to the terms of the Amended Facilities.

[**Table of Contents**](#TOC)

Our obligations under the Amended Facilities and the Subsidiary Guarantors' obligations under the related guarantees were secured by (i) a first-priority lien on all of the Subsidiary Guarantors' cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the "ABL priority collateral") and (ii) a second-priority lien on all of the Subsidiary Guarantors' equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and all other assets that did not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations.

The Amended Credit Agreement allowed us to have outstanding, at any time, up to an aggregate principal amount of $1.5 billion in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Amended Facilities and other existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock matured or required scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Amended Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that was 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Amended Credit Agreement additionally allowed us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Amended Credit Agreement) was not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that could be incurred if certain interest coverage levels were not met at the time of incurrence or other exemptions are not available. The Amended Credit Agreement also contained certain restrictions on the amount of secured first priority debt we are able to incur. The Amended Credit Agreement also allowed for the voluntary repurchase of any debt or other convertible debt, so long as the Amended Facilities were not in default and we maintained availability under our revolver of more than $365.0 million.

The Amended Credit Agreement had a financial covenant that required us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Senior Secured Revolving Credit Facility was less than $200.0 million or (ii) on the third consecutive business day on which availability under the Senior Secured Revolving Credit Facility was less than $250.0 million and, in each case, ending on and excluding the first day thereafter, if any, which was the 30th consecutive calendar day on which availability under the revolver was equal to or greater than $250.0 million. As of November 26, 2022, the availability under the Senior Secured Revolving Credit Facility was at a level that did not trigger the Amended Credit Agreement's financial covenant. The Amended Credit Agreement also contained covenants which placed restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Amended Credit Agreement provided for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It would also be an event of default if we failed to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurred that enabled, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment repurchase, redemption or defeasance of such debt.

On December 1, 2022, we entered into the Third Amendment to Credit Agreement (the "Third Amendment"), which, among other things, amended the Amended Credit Agreement (the Amended Credit Agreement, as modified by the Third Amendment, the "Currently Effective Credit Agreement") to provide for a $2.85 billion senior secured asset-based revolving credit facility (the "Currently Effective Senior Secured Revolving Credit Facility") and a $400.0 million "first-in, last-out" senior secured term loan facility (the "Currently Effective Senior Secured Term Loan" and, together with the Currently Effective Senior Secured Revolving Credit Facility, collectively, the "Currently Effective Facilities"), replaced the LIBOR rate with a Term SOFR-based rate as the applicable benchmark for the Currently Effective Facilities, include COVID-19 vaccines in the borrowing base under the Currently Effective Senior Secured Revolving Credit Facility, subject to limitations and conditions as specified in the Currently Effective Credit Agreement, and increased the interest rate applicable to loans under the Currently Effective Senior Secured Term Loan to (x) a base rate (determined in a customary manner) plus a margin of 2.00% or (y) an adjusted Term SOFR-based rate (determined in a customary manner) plus a margin of 3.00%.

[**Table of Contents**](#TOC)

We are required to pay fees between 0.250% and 0.375% per annum on the daily unused amount of the commitments under the Currently Effective Senior Secured Revolving Credit Facility, depending on Average ABL Availability (as defined in the Currently Effective Credit Agreement). The Currently Effective Facilities are scheduled to mature on August 20, 2026 (subject to a springing maturity if certain of our existing secured notes are not refinanced or repaid prior to the date that is 91 days prior to the stated maturity thereof).

Our borrowing capacity under the Currently Effective Senior Secured Revolving Credit Facility is based upon a specified borrowing base consisting of accounts receivable, inventory and prescription files. If at any time the total credit exposure outstanding under the Currently Effective Senior Secured Revolving Credit Facility exceeds the borrowing base, we will be required to repay amounts outstanding to eliminate such shortfall.

The Currently Effective Credit Agreement restricts us and all of our subsidiaries, including the subsidiaries that guarantee our obligations under the Currently Effective Facilities, the secured guaranteed notes and unsecured guaranteed notes (collectively, the "Subsidiary Guarantors") from accumulating cash on hand in excess of $200.0 million at any time when revolving loans are outstanding (not including cash located in store and lockbox deposit accounts and cash necessary to cover our current liabilities). The Currently Effective Credit Agreement also states that if at any time (other than following the exercise of remedies or acceleration of any senior obligations or second priority debt and receipt of a triggering notice by the senior collateral agent from a representative of the senior obligations or the second priority debt) either (i) an event of default exists under the Currently Effective Facilities or (ii) the sum of our borrowing capacity under the Currently Effective Senior Secured Revolving Credit Facility and certain amounts held on deposit with the senior collateral agent in a concentration account is less than or equal to $283.25 million for three consecutive business days or less than or equal to $206 million on any day (a "cash sweep period"), the funds in our deposit accounts will be swept to a concentration account with the senior collateral agent and will be applied first to repay outstanding revolving loans under the Currently Effective Facilities, and then held as collateral for the senior obligations until such cash sweep period is rescinded pursuant to the terms of the Currently Effective Facilities.

Our obligations under the Currently Effective Facilities and the Subsidiary Guarantors' obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors' cash and cash equivalents, accounts receivable, inventory, prescription files (including eligible script lists), intellectual property (prior to the repayment of the Currently Effective Senior Secured Term Loan) and certain other assets arising therefrom or related thereto (including substantially all of their deposit accounts, collectively, the "ABL priority collateral") and (ii) a second-priority lien on all of the Subsidiary Guarantors' equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Currently Effective Senior Secured Term Loan) and all other assets that do not constitute ABL priority collateral, in each case, subject to customary exceptions and limitations.

The Currently Effective Credit Agreement allows us to have outstanding, at any time, up to an aggregate principal amount of $1.5 billion in secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock in addition to borrowings under the Currently Effective Facilities and existing indebtedness, provided that not in excess of $750.0 million of such secured second priority debt, split-priority debt, unsecured debt and disqualified preferred stock shall mature or require scheduled payments of principal prior to 90 days after the latest maturity date of any Term Loan or Other Revolving Commitment (each as defined in the Currently Effective Credit Agreement) (excluding bridge facilities allowing extensions on customary terms to at least the date that is 90 days after such date). Subject to the limitations described in the immediately preceding sentence, the Currently Effective Credit Agreement additionally allows us to issue or incur an unlimited amount of unsecured debt and disqualified preferred stock so long as a Financial Covenant Effectiveness Period (as defined in the Currently Effective Credit Agreement) is not in effect; provided, however, that certain of our other outstanding indebtedness limits the amount of unsecured debt that can be incurred if certain interest coverage levels are not met at the time of incurrence or other exemptions are not available. The Currently Effective Credit Agreement also contains certain restrictions on the amount of secured first priority debt we are able to incur. The Currently Effective Credit Agreement also allows for the voluntary repurchase of any debt or other convertible debt, so long as the Currently Effective Facilities are not in default and we maintain availability under its revolver of more than $375.95 million.

[**Table of Contents**](#TOC)

The Currently Effective Credit Agreement has a financial covenant that requires us to maintain a minimum fixed charge coverage ratio of 1.00 to 1.00 (i) on any date on which availability under the Currently Effective Senior Secured Revolving Credit Facility is less than $206.0 million or (ii) on the third consecutive business day on which availability under the Currently Effective Senior Secured Revolving Credit Facility is less than $257.5 million and, in each case, ending on and excluding the first day thereafter, if any, which is the 30th consecutive calendar day on which availability under the revolver is equal to or greater than $257.5 million. The Currently Effective Credit Agreement also contains covenants which place restrictions on the incurrence of debt, the payments of dividends, the making of investments, sale of assets, mergers and acquisitions and the granting of liens.

The Currently Effective Credit Agreement provides for customary events of default including nonpayment, misrepresentation, breach of covenants and bankruptcy. It is also an event of default if we fail to make any required payment on debt having a principal amount in excess of $50.0 million or any event occurs that enables, or which with the giving of notice or the lapse of time would enable, the holder of such debt to accelerate the maturity or require the repayment, repurchase, redemption or defeasance of such debt.

The indentures that govern our secured notes contain restrictions on the amount of additional secured and unsecured debt that we may incur. As of November 26, 2022, we had the ability to issue additional secured and unsecured debt under the indentures governing our secured notes, including the ability to draw the full amount of our Senior Secured Revolving Credit Facility and enter into certain sale and leaseback transactions. We also have certain limitations in our unguaranteed unsecured notes on the amount of secured debt that we may incur. We have additional debt incurrence capacity under such indentures.

*Guarantor Summarized Financial Information*

Certain of our subsidiaries, which are listed on Exhibit 22 to this Quarterly Report on Form 10-Q, have guaranteed our obligations under the 7.500% Notes and the 8.00% Notes (collectively, the "Guaranteed Notes"). As discussed in Note 11 to the condensed consolidated financial statements, the Guaranteed Notes were issued by us, as the parent company, and are guaranteed by substantially all of the parent company's consolidated subsidiaries (the "guarantors" or "Subsidiary Guarantors") except for EI (the "non-guarantor"). The parent company and guarantors are referred to as the "obligor group". The Subsidiary Guarantors fully and unconditionally and jointly and severally guarantee the Guaranteed Notes. The 7.500% Notes, the 8.00% Notes and the obligations under the related guarantees are secured by (i) a first-priority lien on all of the Subsidiary Guarantors' equipment, fixtures, investment property (other than equity interests in subsidiaries), intellectual property (following the repayment of the Senior Secured Term Loan) and other collateral to the extent it does not constitute ABL priority collateral (as defined below), and (ii) a second-priority lien on all of the Subsidiary Guarantors' cash and cash equivalents, accounts receivables, payment intangibles, inventory, prescription files (including eligible script lists) and, intellectual property (prior to the repayment of the Senior Secured Term Loan) (collectively, the "ABL priority collateral"), which, in each case, also secure the Amended Facilities.

Under certain circumstances, subsidiaries may be released from their guarantees without consent of the note holders. Our subsidiaries conduct substantially all of our operations and have significant liabilities, including trade payables. If the subsidiary guarantees are invalid or unenforceable or are limited by fraudulent conveyance or other laws, the registered debt will be structurally subordinated to the substantial liabilities of our subsidiaries.

*Condensed Combined Financial Information*

The following tables include summarized financial information of the obligor group. Investments in and the equity in the earnings of EI, which is not a member of the obligor group, have been excluded. The summarized financial information of the obligor group is presented on a combined basis with intercompany balances and transactions between entities in the obligor group eliminated. The obligor group's amounts due to/from and transactions with EI have been presented in separate line items, if material.

[**Table of Contents**](#TOC)

---

| | | |
|:---|:---|:---|
| <br>**In millions** | **November 26,**<br>**2022** | **February 26,**<br>**2022** |
| Due from EI | $188.6 | $26.5 |
| Other current assets | 3386.2 | 3314.9 |
| &nbsp;&nbsp;Total current assets | $3574.8 | $3341.4 |
| Operating lease right-of-use assets | $2623.0 | $2813.5 |
| Goodwill | 626.9 | 879.1 |
| Other noncurrent assets | 1321.3 | 1428.8 |
| &nbsp;&nbsp;Total noncurrent assets | $4571.2 | $5121.4 |
| Due to EI | $— | $— |
| Other current liabilities | 2768.4 | 2891.1 |
| &nbsp;&nbsp;Total current liabilities | $2768.4 | $2891.1 |
| Long-term debt less current maturities | $3189.0 | $2733.0 |
| Long-term operating lease liabilities | 2427.8 | 2597.1 |
| Other noncurrent liabilities | 164.5 | 142.7 |
| &nbsp;&nbsp;Total noncurrent liabilities | $5781.3 | $5472.8 |

---

---

| | | |
|:---|:---|:---|
| **In millions** | **Thirteen Week Period Ended**<br>**November 26, 2022** | **Thirty-Nine Week Period Ended**<br>**November 26, 2022** |
| Revenues<sup>(a)</sup> | $5940.7 | $17570.4 |
| Cost of revenues<sup>(b)</sup> | 4735.5 | 14017.2 |
| &nbsp;&nbsp;Gross profit | 1205.2 | 3553.2 |
| Net loss  | $(68.5) | $(492.7) |
| Net loss attributable to Rite Aid | $(67.1) | $(508.6) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Includes $(27.4) million and $(0.4) million of revenues generated from the non-guarantor for the thirteen and thirty-nine week periods ended November 26, 2022 .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Includes $(27.5) million and $(0.6) million of cost of revenues incurred in transactions with the non-guarantor for the thirteen and thirty-nine week periods ended November 26, 2022 .

*Net Cash Provided by/Used in Operating, Investing and Financing Activities*

Cash used in operating activities was $318.9 million compared to cash provided by operating activities of $36.6 million for the thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. Operating cash flow was negatively impacted by the build of the CMS receivable, increases in inventory due to seasonal build and inflation and the timing of warehouse and third party payables.

Cash used in investing activities was $90.6 million and $111.2 million for the thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. During the thirty-nine week period ended November 26, 2022, we spent $172.6 million on the purchase of property, plant and equipment, $24.9 million on prescription file purchases, received proceeds of $55.9 million from sale leasebacks of two distribution centers and five retail stores, and received $51.0 million primarily from prescription file sales driven by our store closures.

Cash flow provided by financing activities was $472.8 million compared to cash provided by financing activities of $69.1 million for the thirty-nine week periods ended November 26, 2022 and November 27, 2021, respectively. Cash provided by financing activities for the thirty-nine weeks ended November 26, 2022 reflects incremental revolver borrowings, partially offset by the repurchase of certain bonds and the change in our zero balance accounts due to timing of payments.

[**Table of Contents**](#TOC)

*Capital Expenditures*

During the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021 capital expenditures were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
| New store construction, store relocation and store remodel projects | $12121 | $11624 | $37794 | $70584 |
| Technology enhancements, improvements to distribution centers and other corporate requirements | 38199 | 28021 | 134769 | 74417 |
| Purchase of prescription files from other retail pharmacies | 9581 | 9810 | 24937 | 24289 |
| Total capital expenditures | $59901 | $49455 | $197500 | $169290 |

---

The Company anticipates incurring approximately $225,000 of capital expenditures during fiscal 2023.

*Future Liquidity*

We are highly leveraged. Our high level of indebtedness could: (i) limit our ability to obtain additional financing; (ii) limit our flexibility in planning for, or reacting to, changes in our business and the industry; (iii) place us at a competitive disadvantage relative to our competitors with less debt; (iv) render us more vulnerable to general adverse economic and industry conditions, including those resulting from COVID-19, a decline in the overall economy, and the current rising interest rate environment; and (v) require us to dedicate a substantial portion of our cash flow to service our debt. Additionally, we currently expect continued pressure on consumer spending and supply chain challenges. Based upon our current levels of operations, we believe that cash flow from operations together with available borrowings under the revolver and other sources of liquidity will be adequate to meet our requirements for working capital, debt service, capital expenditures and other strategic investments at least for the next twelve months. Based on our liquidity position, which we expect to remain strong, we do not expect to be subject to the minimum fixed charge covenant in the Amended Facilities in the next twelve months. We will continue to assess our liquidity position and potential sources of supplemental liquidity in light of our operating performance, and other relevant circumstances, and we may evaluate alternative sources of liquidity (particularly in light of the current market volatility), including further opportunities related to any receivable due to us from CMS, sale and leaseback transactions, and other transactions to optimize our asset base. From time to time, we may seek additional deleveraging or refinancing transactions, including entering into transactions to exchange debt for shares of common stock or other debt securities (including additional secured debt), issuance of equity (including preferred stock and convertible securities), repurchase or redemption of outstanding indebtedness, including our recent cash tender offers whereby we purchased $150.0 million of certain of our outstanding series of senior notes as announced on June 13, 2022 and $165.1 million of our outstanding 7.500% Senior Secured Notes due 2025 as announced on November 3, 2022, or seek to refinance our outstanding debt or may otherwise seek transactions to reduce interest expense and extend debt maturities. We may also look to make additional investments in our business to further our strategic objectives, including targeted acquisitions or other transactions to optimize our asset base. Any of these transactions could impact our financial results, including additional changes or realization of cancellation of indebtedness-income. As a result of the current market volatility and rising interest rate environment, we cannot assure you whether any of such transactions will be consummated, whether we will achieve the benefits of any such transaction, or whether our cost of capital will increase, any of which could have an impact on our future liquidity.

**Critical Accounting Policies and Estimates**

For a description of the critical accounting policies that require the use of significant judgments and estimates by management, refer to "Management's Discussion and Analysis of Financial Condition and Results—Critical Accounting Policies and Estimates" included in our Fiscal 2022 10-K, which we filed with the SEC on April 25, 2022.

[**Table of Contents**](#TOC)

**Factors Affecting Our Future Prospects**

For a discussion of risks related to our financial condition, operations and industry, refer to "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results" included in our Fiscal 2022 10-K.

**Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures**

In addition to net income (loss) determined in accordance with GAAP, we use certain non-GAAP measures, such as "Adjusted EBITDA", in assessing our operating performance. We believe the non-GAAP measures serve as an appropriate measure in evaluating the performance of our business. We define Adjusted EBITDA as net income (loss) excluding the impact of income taxes, interest expense, depreciation and amortization, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), charges or credits for facility closing and impairment, goodwill and intangible asset impairment charges, inventory write-downs related to store closings, gains or losses on debt modifications and retirements, and other items (including stock-based compensation expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, severance, restructuring-related costs and costs related to facility closures, gain or loss on sale of assets and the loss on Bartell acquisition). We reference this particular non-GAAP financial measure frequently in our decision-making because it provides supplemental information that facilitates internal comparisons to the historical periods and external comparisons to competitors. In addition, incentive compensation is primarily based on Adjusted EBITDA and we base certain of our forward-looking estimates on Adjusted EBITDA to facilitate quantification of planned business activities and enhance subsequent follow-up with comparisons of actual to planned Adjusted EBITDA.

The following is a reconciliation of our net income (loss) to Adjusted EBITDA for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Net loss | $(67144) | $(36058) | $(508625) | $(149416) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | 57416 | 47794 | 158068 | 145507 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax (benefit) expense  | (510) | (1175) | 14954 | 2915 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 69496 | 72973 | 208133 | 222691 |
| &nbsp;&nbsp;&nbsp;&nbsp;LIFO charge | 15246 | 8886 | 25367 | 900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Facility exit and impairment charges | 22539 | 47455 | 134955 | 67639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangible asset impairment charges |  |  | 252200 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on debt modifications and retirements, net |  |  | (41312) | 3235 |
| &nbsp;&nbsp;&nbsp;&nbsp;Merger and Acquisition-related costs |  | 3642 |  | 12119 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 566 | 217 | 8635 | 8820 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring-related costs | 26500 | 9657 | 61951 | 25173 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory write-downs related to store closings | 3085 | 86 | 12134 | 1356 |
| &nbsp;&nbsp;&nbsp;&nbsp;Litigation and other contractual settlements | (2541) | 2000 | 35823 | 50212 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of assets, net | (3095) | (5899) | (61292) | (79) |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |  | 5346 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | 358 | (131) | (396) | 3412 |
| Adjusted EBITDA | $121916 | $154793 | $300595 | $399830 |

---

The following is a reconciliation of our net income (loss) to Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share for the thirteen and thirty-nine week periods ended November 26, 2022 and November 27, 2021. Adjusted Net Income (Loss) is defined as net income (loss) excluding the impact of amortization expense, merger and acquisition-related costs, non-recurring litigation and other contractual settlements, gains or losses on debt modifications and retirements, LIFO adjustments (which removes the entire impact of LIFO, and effectively reflects the results as if we were on a FIFO inventory basis), goodwill and intangible asset impairment charges, restructuring-related

[**Table of Contents**](#TOC)

costs, and the loss on Bartell acquisition. We calculate Adjusted Net Income (Loss) per Diluted Share using our above-referenced definition of Adjusted Net Income (Loss). We believe Adjusted Net Income (Loss) and Adjusted Net Income (Loss) per Diluted Share are useful indicators of our operating performance over multiple periods.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Thirteen Week Period Ended** | **Thirteen Week Period Ended** | **Thirty-Nine Week Period Ended** | **Thirty-Nine Week Period Ended** |
|  | **November 26,**<br>**2022** | **November 27,**<br>**2021** | **November 26,**<br>**2022** | **November 27,**<br>**2021** |
|  | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** | **(dollars in thousands)** |
| Net loss | $(67144) | $(36058) | $(508625) | $(149416) |
| &nbsp;&nbsp;&nbsp;&nbsp;Add back - Income tax (benefit) expense | (510) | (1175) | 14954 | 2915 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss before income taxes | (67654) | (37233) | (493671) | (146501) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization expense | 17622 | 18780 | 56668 | 59193 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIFO charge | 15246 | 8886 | 25367 | 900 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and intangible asset impairment charges |  |  | 252200 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(Gain) loss on debt modifications and retirements, net |  |  | (41312) | 3235 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merger and Acquisition-related costs |  | 3642 |  | 12119 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring-related costs | 26500 | 9657 | 61951 | 25173 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on Bartell acquisition |  | 5346 |  | 5346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation and other contractual settlements | (2541) | 2000 | 35823 | 50212 |
| Adjusted (loss) income before income taxes  | (10827) | 11078 | (102974) | 9677 |
| Adjusted income tax (benefit) expense (a) | (2897) | 2914 | (27556) | 2545 |
| Adjusted net (loss) income | (7930) | $8164 | $(75418) | $7132 |
| Net loss per diluted share | $(1.23) | $(0.67) | $(9.32) | $(2.77) |
| Adjusted net (loss) income per diluted share | $(0.14) | $0.15 | $(1.38) | $0.13 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(a) The fiscal year 2023 and 2022 annual effective tax rates, calculated using a federal rate plus a net state rate that excluded the impact of state NOL's, state credits and valuation allowance, was used for the thirteen and thirty-nine weeks ended November 26, 2022 and November 27, 2021 , respectively.

In addition to Adjusted EBITDA, Adjusted Net (Loss) Income and Adjusted Net (Loss) Income per Diluted Share, we occasionally refer to several other Non-GAAP measures, on a less frequent basis, in order to describe certain components of our business and how we utilize them to describe our results. These measures include but are not limited to Adjusted EBITDA Gross Margin and Gross Profit (gross margin/gross profit excluding non-Adjusted EBITDA items), Adjusted EBITDA SG&A (SG&A expenses excluding non-Adjusted EBITDA items), FIFO Gross Margin and FIFO Gross Profit (gross margin/gross profit before LIFO charges), and Free Cash Flow (Adjusted EBITDA less cash paid for interest, rent on closed stores, capital expenditures, restructuring-related costs and the change in working capital).

We include these non-GAAP financial measures in our earnings announcements in order to provide transparency to our investors and enable investors to better compare our operating performance with the operating performance of our competitors including with those of our competitors having different capital structures. Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share or other non-GAAP measures should not be considered in isolation from, and are not intended to represent an alternative measure of, operating results or of cash flows from operating activities, as determined in accordance with GAAP. Our definition of these non-GAAP measures may not be comparable to similarly titled measurements reported by other companies.

**ITEM 3. Quantitative and Qualitative Disclosures About Market Risk**

Our future earnings, cash flow and fair values relevant to financial instruments are dependent upon prevalent market rates. Market risk is the risk of loss from adverse changes in market prices and interest rates. Our major market risk exposure is changing interest rates. Increases in interest rates would increase our interest expense. We enter into debt obligations to support capital expenditures, acquisitions, working capital needs and general corporate purposes. Our

[**Table of Contents**](#TOC)

policy is to manage interest rates through the use of a combination of variable-rate credit facilities, fixed-rate long-term obligations and derivative transactions.

The table below provides information about our financial instruments that are sensitive to changes in interest rates. The table presents principal payments and the related weighted average interest rates by expected maturity dates as of November 26, 2022.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **2023** | **2024** | **2025** | **2026** | **2027** | <br>**Thereafter** | <br>**Total** | **Fair Value at**<br>**November 26, 2022** |
|  | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** | **(Dollars in thousands)** |
| **Long-term debt, including current portion, excluding financing lease obligations** |  |  |  |  |  |  |  |  |
| Fixed Rate | $— | $— | $— | $485058 | $1035609 | $2046 | $1522713 | $986945 |
| Average Interest Rate | 0.00% | 0.00% | 0.00% | 7.50% | 7.95% | 6.88% | 7.80% |  |
| Variable Rate | $— | $— | $— | $— | $1700000 | $— | $1700000 | $1700000 |
| Average Interest Rate | 0.00% | 0.00% | 0.00% | 0.00% | 4.98% | 0.00% | 4.98% |  |

---

Our ability to satisfy interest payment obligations on our outstanding debt will depend largely on our future performance, which, in turn, is subject to prevailing economic conditions and to financial, business and other factors beyond our control. If we do not have sufficient cash flow to service our interest payment obligations on our outstanding indebtedness and if we cannot borrow or obtain equity financing to satisfy those obligations, our business and results of operations could be materially adversely affected. We cannot be assured that any replacement borrowing or equity financing could be successfully completed.

The interest rate on our variable rate borrowings, which include our revolving credit facility and our term loan facility, are based on LIBOR. If the market rates of interest for LIBOR changed by 100 basis points as of November 26, 2022, our annual interest expense would change by approximately $17.0 million.

A change in interest rates does not have an impact upon our future earnings and cash flow for fixed-rate debt instruments. As fixed-rate debt matures, however, and if additional debt is acquired to fund the debt repayment, future earnings and cash flow may be affected by changes in interest rates. This effect would be realized in the periods subsequent to the periods when the debt matures. Increases in interest rates would also impact our ability to refinance existing maturities on favorable terms.

**ITEM 4. Controls and Procedures**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Disclosure Controls and Procedures*

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such period, our disclosure controls and procedures are effective.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b) Changes in Internal Control over Financial Reporting*

There have not been any changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter to which this report relates that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

[**Table of Contents**](#TOC)

**PART II. OTHER INFORMATION**

**ITEM 1. Legal Proceedings**

The information in response to this item is incorporated herein by reference to Note 16, Commitments, Contingencies and Guarantees, of the Consolidated Condensed Financial Statements of this Quarterly Report.

**ITEM 1A. Risk Factors**

In addition to the information set forth in this Quarterly Report, you should carefully consider the factors discussed in "Part I — Item 1A. Risk Factors" in our Fiscal 2022 10-K, which could materially affect our business, financial condition or future results.

**ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds**

*Issuer Repurchases of Equity Securities.* The table below is a listing of repurchases of common stock during the third quarter of fiscal 2023.

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Fiscal period:** | **Total**<br>**Number of**<br>**Shares**<br>**Repurchased** | <br>**Average**<br>**Price Paid**<br>**Per Share** | **Total Number of Shares**<br>**Purchased as Part of**<br>**Publicly Announced**<br>**Plans or Programs** | **Maximum Number of**<br>**Shares that may yet be**<br>**Purchased under the**<br>**Plans or Programs** |
| August 28, 2022 to September 24, 2022 | 8 | $7.72 |  |  |
| September 25, 2022 to October 22, 2022 | 3 | $5.20 |  |  |
| October 23, 2022 to November 26, 2022 | 1 | $5.49 |  |  |

---

**ITEM 3. Defaults Upon Senior Securities**

Not applicable.

**ITEM 4. Mine Safety Disclosures**

Not applicable.

**ITEM 5. Other Information**

Not applicable.

**ITEM 6. Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The following exhibits are filed as part of this report.

---

| | | |
|:---|:---|:---|
| **Exhibit**<br>**Numbers** | **Description** | **Incorporation By Reference To** |
| 2.1 | [Receivable Purchase Agreement, dated as of August 12, 2021, by and between Envision Insurance Company and Part D Receivable Trust 2020-1 (Series D)](https://www.sec.gov/Archives/edgar/data/84129/000110465921104651/tm2124941d1_ex2-1.htm)  | Exhibit 2.1 to Form 8-K, filed on August 13, 2021 |
| 2.2 | [Indemnity Agreement, dated as of August 12, 2021 by and between Rite Aid Corporation and Part D Receivable Trust 2020-1 (Series D)](https://www.sec.gov/Archives/edgar/data/0000084129/000110465921104651/tm2124941d1_ex2-1.htm)  | Exhibit 2.2 to Form 8-K, filed on August 13, 2021  |
| 2.3 | [Receivable Purchase Agreement, dated as of January 24, 2022 February 19, 2020, by and between Envision Insurance Company and Part D Receivable Trust 2020-1 (Series E)](https://www.sec.gov/Archives/edgar/data/0000084129/000110465922006972/tm224167d1_ex2-1.htm)  | Exhibit 2.1 to Form 8-K, filed on January 24, 2022  |

---

[**Table of Contents**](#TOC)

---

| | | |
|:---|:---|:---|
| **Exhibit**<br>**Numbers** | **Description** | **Incorporation By Reference To** |
| 2.4 | [Indemnity Agreement, dated as of January 24, 2022 by and between Rite Aid Corporation and Part D Receivable Trust 2020-1 (Series D)](https://www.sec.gov/Archives/edgar/data/0000084129/000110465922006972/tm224167d1_ex2-1.htm)  | Exhibit 2.2 to Form 8-K, filed on January 24, 2022  |
| 2.5 | [Receivable Purchase Agreement, dated as of October 13, 2022, by and between Elixir Insurance Company and Part D Receivable Trust 2020-1 (Series F)](https://www.sec.gov/Archives/edgar/data/84129/000110465922108598/tm2228089d1_ex2-1.htm) | Exhibit 2.1 Filed to Form 8-K, filed on October 14, 2022 |
| 2.6 | [Indemnity Agreement, dated as of October 13, 2022 by and between Rite Aid Corporation and Part D Receivable Trust 2020-1 (Series F)](https://www.sec.gov/Archives/edgar/data/84129/000110465922108598/tm2228089d1_ex2-1.htm) | Exhibit 2.2 Filed to Form 8-K, filed on October 14, 2022 |
| 3.1 | [Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/84129/000104746914004077/a2219729zex-3_1.htm) | Exhibit 3.1 to Form 10-K, filed on April 23, 2014 |
| 3.2 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/84129/000110465919022372/a19-8544_1ex3d1.htm) | Exhibit 3.1 to Form 8-K, filed on April 18, 2019 |
| 3.3 | [Amended and Restated By-Laws](http://www.sec.gov/Archives/edgar/data/84129/000110465920048201/tm2016166d1_ex3-1.htm) | Exhibit 3.1 to Form 8-K, filed on April 17, 2020 |
| 4.1 | Indenture, dated as of August 1, 1993, between Rite Aid Corporation, as issuer, and Morgan Guaranty Trust Company of New York, as trustee, related to the Company's 7.70% Notes due 2027 | Exhibit 4A to Registration Statement on Form S-3, File No. 033-63794, filed on June 3, 1993 |
| 4.2 | [Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and U.S. Bank Trust National Association (as successor trustee to Morgan Guaranty Trust Company of New York) to the Indenture dated as of August 1, 1993, between Rite Aid Corporation and Morgan Guaranty Trust Company of New York, relating to the Company's 7.70% Notes due 2027](http://www.sec.gov/Archives/edgar/data/84129/0000950172-00-000182-index.html) | Exhibit 4.1 to Form 8-K filed on February 7, 2000 |
| 4.3 | [Indenture, dated as of December 21, 1998, between Rite Aid Corporation, as issuer, and Harris Trust and Savings Bank, as trustee, related to the Company's 6.875% Notes due 2028](http://www.sec.gov/Archives/edgar/data/84129/0000950130-99-001573-index.html) | Exhibit 4.1 to Registration Statement on Form S-4, File No. 333-74751, filed on March 19, 1999 |
| 4.4 | [Supplemental Indenture, dated as of February 3, 2000, between Rite Aid Corporation and Harris Trust and Savings Bank to the Indenture, dated December 21, 1998, between Rite Aid Corporation and Harris Trust and Savings Bank, related to the Company's 6.875% Notes due 2028](http://www.sec.gov/Archives/edgar/data/84129/0000950172-00-000182-index.html) | Exhibit 4.4 to Form 8-K, filed on February 7, 2000 |
| 4.5 | [Indenture, dated as of February 5, 2020, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company's 7.500% Senior Secured Notes due 2025](https://www.sec.gov/Archives/edgar/data/84129/000110465920011356/tm206757d1_ex4-1.htm)  | Exhibit 4.1 to Form 8-K filed on February 5, 2020  |
| 4.6 | [Description of the Company's securities registered pursuant to Section 12 of the Securities Exchange Act of 1934](https://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex4d9.htm)  | Exhibit 4.9 to Form 10-K filed on April 27, 2020  |
| 4.7 | [Indenture, dated as of July 27, 2020, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., related to the Company's 8.000% Senior Secured Notes due 2026](https://www.sec.gov/Archives/edgar/data/84129/000110465920086863/tm2025755d1_ex4-1.htm)  | Exhibit 4.1 to Form 8-K filed on July 27, 2020  |
| 4.8 | [Supplemental Indenture, dated as of August 27, 2021, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of February 5, 2020, related to the Company's 7.500% Senior Secured Notes due 2025](https://www.sec.gov/Archives/edgar/data/84129/000155837021012998/rad-20210828xex4d12.htm) | Exhibit 4.12 to Form 10-Q filed on October 5, 2021 |

---

[**Table of Contents**](#TOC)

---

| | | | |
|:---|:---|:---|:---|
| <br>**Exhibit**<br>**Numbers** | **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**  | <br>**Description** | <br>**Incorporation By Reference To** |
| 4.9 |  | [Supplemental Indenture, dated as of August 27, 2021, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of July 27, 2020, related to the Company's 8.000% Senior Secured Notes due 2026](https://www.sec.gov/Archives/edgar/data/84129/000155837021012998/rad-20210828xex4d13.htm) | Exhibit 4.13 to Form 10-Q filed on October 5, 2021 |
| 4.10 |  | [Supplemental Indenture, dated as of March 31, 2022, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of February 5, 2020, related to the Company's 7.500% Senior Secured Notes due 2025](https://www.sec.gov/Archives/edgar/data/84129/000155837022010556/rad-20220528xex4d10.htm) | Exhibit 4.10 to Form 10-Q, filed on July 6, 2022 |
| 4.11 |  | [Supplemental Indenture, dated as of March 31, 2022, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of July 27, 2020, related to the Company's 8.000% Senior Secured Notes due 2026](https://www.sec.gov/Archives/edgar/data/84129/000155837022010556/rad-20220528xex4d11.htm) | Exhibit 4.11 to Form 10-Q, filed on July 6, 2022 |
| 4.12 |  | [Supplemental Indenture, dated as of September 19, 2022, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of February 5, 2020, related to the Company's 7.500% Senior Secured Notes due 2025](rad-20221126xex4d12.htm) | Filed herewith |
| 4.13 |  | [Supplemental Indenture, dated as of September 19, 2022, among Rite Aid Corporation, the subsidiary guarantors named therein and The Bank of New York Mellon Trust Company, N.A., to the Indenture, dated as of July 27, 2020, related to the Company's 8.000% Senior Secured Notes due 2026](rad-20221126xex4d13.htm) | Filed herewith |
| 10.1 | † | [2010 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000095017210000028/exhibit10-1.htm) | Exhibit 10.1 to Form 8-K, filed on June 25, 2010 |
| 10.2 | † | [Amendment No. 1, dated September 21, 2010, to the 2010 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000104746910008476/a2200331zex-10_7.htm) | Exhibit 10.7 to Form 10-Q, filed on October 7, 2010 |
| 10.3 | † | [Amendment No. 2, dated January 16, 2013, to the 2010 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000104746913004721/a2214454zex-10_8.htm) | Exhibit 10.8 to Form 10-K, filed on April 23, 2013 |
| 10.4 | † | [2012 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000110465912045553/a12-14905_2ex10d1.htm) | Exhibit 10.1 to Form 8-K, filed on June 25, 2012 |
| 10.5 | † | [Amendment No. 1, dated January 16, 2013, to the 2012 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000104746913004721/a2214454zex-10_10.htm) | Exhibit 10.10 to Form 10-K, filed on April 23, 2013 |
| 10.6 | † | [2014 Omnibus Equity Plan](http://www.sec.gov/Archives/edgar/data/84129/000110465914047743/a14-15665_2ex10d1.htm) | Exhibit 10.1 to Form 8-K, filed on June 23, 2014 |
| 10.7 | † | [Form of Award Agreement](http://www.sec.gov/Archives/edgar/data/84129/000110465912037497/a12-12163_1ex10d2.htm) | Exhibit 10.2 to Form 8-K, filed on May 15, 2012 |
| 10.8 | † | [Executive Incentive Plan for Officers of Rite Aid Corporation](http://www.sec.gov/Archives/edgar/data/84129/000134100412000332/rad_ex10-1.htm) | Exhibit 10.1 to Form 8-K, filed on February 24, 2012 |
| 10.9 | † | [Employment Agreement by and between Rite Aid Corporation and Jocelyn Konrad dated as of August 18, 2015](http://www.sec.gov/Archives/edgar/data/84129/000110465916088371/a15-24100_1ex10d1.htm) | Exhibit 10.1 to Form 10-Q, filed on January 6, 2016 |
| 10.10 |  | [Credit Agreement, dated as of December 20, 2018, among Rite Aid Corporation, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent and collateral agent.](http://www.sec.gov/Archives/edgar/data/84129/000110465918074132/a18-41929_1ex10d1.htm) | Exhibit 10.1 to Form 8-K, filed on December 20, 2018 |

---

[**Table of Contents**](#TOC)

---

| | | | |
|:---|:---|:---|:---|
| <br>**Exhibit**<br>**Numbers** | **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**  | <br>**Description** | <br>**Incorporation By Reference To** |
| 10.11 |  | [First Amendment to Credit Agreement, dated as of January 6, 2020, among Rite Aid Corporation, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent.](https://www.sec.gov/Archives/edgar/data/0000084129/000110465920001791/tm201345d1_ex10-1.htm) | Exhibit 10.1 to Form 8-K, filed on January 7, 2020 |
| 10.12 |  | [Second Amendment to Credit Agreement, dated as of August 20, 2021, among Rite Aid Corporation, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent](https://www.sec.gov/Archives/edgar/data/0000084129/000110465921108487/tm2125671d1_ex9-01.htm) | Exhibit 9.01 to Form 8-K, filed on August 23, 2021 |
| 10.13 |  | [Third Amendment to Credit Agreement, dated as of December 1, 2022, among Rite Aid Corporation, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral agent](https://www.sec.gov/Archives/edgar/data/84129/000110465922124690/tm2232044d1_ex9-01.htm) | Exhibit 9.01 to Form 8-K/A, filed on December 6, 2022 |
| 10.14 |  | [Amended and Restated Collateral Trust and Intercreditor Agreement, including the related definitions annex, dated as of June 5, 2009, among Rite Aid Corporation, each subsidiary named therein or which becomes a party thereto, Wilmington Trust Company, as collateral trustee, Citicorp North America, Inc., as senior collateral processing agent, The Bank of New York Trust Company, N.A., as trustee under the 2017 7.5% Note Indenture (as defined therein) and The Bank of New York Mellon Trust Company, N.A., as trustee under the 2016 10.375% Note Indenture (as defined therein), and each other Second Priority Representative and Senior Representative which becomes a party thereto](http://www.sec.gov/Archives/edgar/data/84129/000134100409001189/ex10-3.htm) | Exhibit 10.3 to Form 8-K, filed on June 11, 2009 |
| 10.15 | † | [Amendment to Employment Agreement by and between Rite Aid Corporation and Jocelyn Z. Konrad, dated as of March 12, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d32.htm) | Exhibit 10.32 to Form 10-Q, filed on July 11, 2019 |
| 10.16 | † | [Amendment to Employment Agreement by and between Rite Aid Corporation and Matthew C. Schroeder, dated as of March 12, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d33.htm) | Exhibit 10.33 to Form 10-Q, filed on July 11, 2019 |
| 10.17 | † | [Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of March 12, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d34.htm) | Exhibit 10.34 to Form 10-Q, filed on July 11, 2019 |
| 10.18 | † | [Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of December 5, 2017](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d35.htm) | Exhibit 10.35 to Form 10-Q, filed on July 11, 2019 |
| 10.19 | † | [Amendment to Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of August 10, 2016](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d36.htm) | Exhibit 10.36 to Form 10-Q, filed on July 11, 2019 |
| 10.20 | † | [Employment Agreement by and between Rite Aid Corporation and Brian Hoover, dated as of January 1, 2001](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d37.htm) | Exhibit 10.37 to Form 10-Q, filed on July 11, 2019 |
| 10.21 | †\* | [Eleventh Amendment to Supply Agreement by and between Rite Aid Corporation and McKesson Corporation, dated as of February 28, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919039944/a19-11433_1ex10d38.htm) | Exhibit 10.38 to Form 10-Q, filed on July 11, 2019 |
| 10.22 | †\*\* | [Employment Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 8, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919045336/a19-17032_1ex10d1.htm) | Exhibit 10.1 to Form 8-K, filed on August 12, 2019 |
| 10.23 | † | [Employment Inducement Award Agreement by and between Rite Aid Corporation and Heyward Donigan, dated August 12, 2019](http://www.sec.gov/Archives/edgar/data/84129/000110465919045336/a19-17032_1ex10d2.htm) | Exhibit 10.2 to Form 8-K, filed on August 12, 2019 |
| 10.24 | † | [Employment Agreement dated October 2, 2019 by and between Rite Aid Corporation and James Peters](http://www.sec.gov/Archives/edgar/data/84129/000110465919052864/a19-19363_1ex10d1.htm) | Exhibit 10.1 to Form 8-K, filed on October 2, 2019 |

---

[**Table of Contents**](#TOC)

---

| | | | |
|:---|:---|:---|:---|
| <br>**Exhibit**<br>**Numbers** | **&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**  | <br>**Description** | <br>**Incorporation By Reference To** |
| 10.25 | † | [Employment Agreement by and between Rite Aid Corporation and Jessica Kazmaier, dated as of March 12, 2019](http://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex10d43.htm) | Exhibit 10.43 to Form 10-K filed on April 27, 2020 |
| 10.26 | † | [Amendment to Employment Agreement by and between Jessica Kazmaier, dated as of November 6, 2019](http://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex10d44.htm) | Exhibit 10.44 to Form 10-K filed on April 27, 2020 |
| 10.27 | † | [Employment Agreement by and between Justin Mennen, dated as of December 7, 2018](http://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex10d45.htm) | Exhibit 10.45 to Form 10-K filed on April 27, 2020 |
| 10.28 | † | [Amendment to Employment Agreement by and between Justin Mennen, dated November 6, 2019](http://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex10d46.htm) | Exhibit 10.46 to Form 10-K filed on April 27, 2020 |
| 10.29 | † | [Employment Agreement by and between Rite Aid Corporation and Andre Persaud, dated as of January 28, 2020](http://www.sec.gov/Archives/edgar/data/84129/000155837020004365/rad-20200229xex10d47.htm) | Exhibit 10.47 to Form 10-K filed on April 27, 2020 |
| 10.30 | † | [Employment Agreement by and between Rite Aid Corporation and Paul D. Gilbert, as of July 29, 2020](https://www.sec.gov/Archives/edgar/data/84129/000155837020011382/rad-20200829xex10d46.htm) | Exhibit 10.46 to Form 10-Q filed on October 6, 2020 |
| 10.31 | † | [Rite Aid Corporation Amended and Restated 2020 Omnibus Equity Plan, as amended](https://www.sec.gov/Archives/edgar/data/84129/000110465922070078/tm228886-2_defc14a.htm) | Appendix B-1 to Schedule 14A (Definitive Proxy Statement) filed on June 10, 2022 |
| 10.32 | † | [Form Award Agreement (Executive) under the Rite Aid Corporation 2020 Omnibus Equity Plan](https://www.sec.gov/Archives/edgar/data/0000084129/000110465920082052/tm2024255d1_ex10-2.htm) | Exhibit 10.2 to Form 8-K filed on July 8, 2020 |
| 10.33 | † | [Form Award Agreement (Non-employee Director) under the Rite Aid Corporation 2020 Omnibus Equity Plan](https://www.sec.gov/Archives/edgar/data/0000084129/000110465920082052/tm2024255d1_ex10-3.htm) | Exhibit 10.3 to Form 8-K filed on July 8, 2020 |
| 10.34 |  | [Separation Agreement by and between Rite Aid Corporation and Jocelyn Konrad, dated as of March 7, 2022](https://www.sec.gov/Archives/edgar/data/84129/000155837022010556/rad-20220528xex10d35.htm) | Exhibit 10.35 to Form 10-Q, filed on July 6, 2022 |
| 10.35 |  | [Separation Agreement by and between Rite Aid Corporation and James Peters, as of March 7, 2022](https://www.sec.gov/Archives/edgar/data/84129/000155837022010556/rad-20220528xex10d36.htm) | Exhibit 10.36 to Form 10-Q, filed on July 6, 2022 |
| 10.36 |  | [Offer Letter, by and between Rite Aid Corporations and Steven K. Bixler dated September 11, 2022](https://www.sec.gov/Archives/edgar/data/84129/000110465922099237/tm2225642d1_ex10-1.htm) | Exhibit 10.1 to Form 8-K, filed on September 12, 2022 |
| 22 |  | [List of Subsidiary Guarantors](rad-20221126xex22.htm) | Filed herewith |
| 31.1 |  | [Certification of CEO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended](rad-20221126xex31d1.htm) | Filed herewith |
| 31.2 |  | [Certification of CFO pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended](rad-20221126xex31d2.htm) | Filed herewith |
| 32 |  | [Certification of CEO and CFO pursuant to 18 United States Code, Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002](rad-20221126xex32.htm) | Filed herewith |
| 101.INS |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Filed herewith |
| 101.SCH |  | XBRL Taxonomy Extension Schema Document. | Filed herewith |
| 101.CAL |  | XBRL Taxonomy Extension Calculation Linkbase Document. | Filed herewith |
| 101.DEF |  | XBRL Taxonomy Extension Definition Linkbase Document. | Filed herewith |
| 101.LAB |  | XBRL Taxonomy Extension Label Linkbase Document. | Filed herewith |
| 101.PRE |  | XBRL Taxonomy Extension Presentation Linkbase Document. | Filed herewith |
| 104 |  | Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | Filed herewith |

---

[**Table of Contents**](#TOC)

\*&nbsp;&nbsp;&nbsp;&nbsp; Confidential portions of this Exhibit were redacted pursuant to Item 601(b)(10) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

\*\* Certain schedules and exhibits to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K and Rite Aid Corporation agrees to furnish supplementally to the Securities and Exchange Commission a copy of any omitted schedule and/or exhibit upon request.

†&nbsp;&nbsp;&nbsp;&nbsp; Management contract or compensatory plan or arrangement.

[**Table of Contents**](#TOC)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 4, 2023 | RITE AID CORPORATION | RITE AID CORPORATION |
|  | By: | /s/ MATTHEW C. SCHROEDER |
|  |  | Matthew C. Schroeder |
|  |  | *Executive Vice President and Chief Financial Officer* |
| Date: January 4, 2023 | By: | /s/ BRIAN T. HOOVER |
|  |  | Brian T. Hoover |
|  |  | *Senior Vice President and Chief Accounting Officer* |

---

## Exhibit 4.12

**Exhibit 4.12**

SUPPLEMENTAL INDENTURE

SUPPLEMENTAL INDENTURE (this "<u>Supplemental Indenture</u>") dated as of September 19, 2022, among Juniper Rx, LLC, a Delaware limited liability company (the "<u>New Subsidiary Guarantor</u>"), a subsidiary of Rite Aid Corporation (or its successor), a Delaware corporation (the "<u>Company</u>"), the Company on behalf of itself and the Subsidiary Guarantors (the "<u>Existing Subsidiary Guarantors</u>") under the indenture referred to below, and The Bank of New York Mellon Trust Company, N.A., a banking association organized under the laws of the United States of America, as trustee (in such capacity, "<u>Trustee</u>") and as notes collateral agent (in such capacity, "<u>Notes Collateral Agent</u>") under the indenture referred to below.

W I T N E S S E T H :

WHEREAS the Company and the Existing Subsidiary Guarantors have heretofore executed and delivered to the Trustee an Indenture (the "<u>Indenture</u>") dated as of February 5, 2020, as amended on August 27, 2021 and March 31, 2022, providing for the issuance of an unlimited aggregate principal amount of 7.500% Senior Secured Notes due 2025 (the "<u>Securities</u>");

WHEREAS Section 4.09 of the Indenture provides that under certain circumstances the Company is required to cause the New Subsidiary Guarantor to execute and deliver to the Trustee a supplemental indenture pursuant to which the New Subsidiary Guarantor shall unconditionally guarantee all the Company's obligations under the Securities pursuant to a Subsidiary Guarantee on the terms and conditions set forth herein; and

WHEREAS pursuant to Section 9.01 of the Indenture, the Trustee, the Company and the Existing Subsidiary Guarantors are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New Subsidiary Guarantor, the Company, the Existing Subsidiary Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Agreement to Guarantee.</u> The New Subsidiary Guarantor hereby agrees, jointly and severally, on a senior secured basis, with all other Subsidiary Guarantors, to unconditionally guarantee the Company's obligations under the Securities and the Indenture on the terms and subject to the conditions set forth in Article X of the Indenture and to be bound by all other applicable provisions of the Indenture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Ratification of Indenture; Supplemental Indentures Part of Indenture.</u> Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Governing Law.</u> **THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK BUT WITHOUT REFERENCE TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Trustee Makes No Representation.</u> The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture and shall not be responsible for the recitals contained herein, all which recitals are made solely by the other parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Counterparts.</u> The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Effect of Headings.</u> The Section headings herein are for convenience only and shall not effect the construction thereof.

[*Remainder of Page Intentionally Left Blank*]

**2**

------

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

JUNIPER RX, LLC

By: */s/* <u>Lisa Winnick</u> <br>Name:Lisa Winnick<br>Title:Vice President and Assistant Secretary

RITE AID CORPORATION, on behalf of itself and the existing subsidiary guarantors

By: */s/* <u>Paul Gilbert</u> <br>Name:Paul Gilbert<br>Title:Executive Vice President, Chief Legal

Officer and Secretary

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as trustee

By: */s/* <u>Shannon Matthews</u> <br>Name:Shannon Matthews<br>Title:Vice President

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as notes collateral agent,

By: */s/* <u>Shannon Matthews</u> <br>Name:Shannon Matthews<br>Title:Vice President

[Signature Page to Supplemental Indenture for the 2025 Notes]

------

## Exhibit 4.13

**Exhibit 4.13**

SUPPLEMENTAL INDENTURE

SUPPLEMENTAL INDENTURE (this "<u>Supplemental Indenture</u>") dated as of September 19, 2022, among Juniper Rx LLC, a Delaware limited liability company (the "<u>New Subsidiary Guarantor</u>"), a subsidiary of Rite Aid Corporation (or its successor), a Delaware corporation (the "<u>Company</u>"), the Company on behalf of itself and the Subsidiary Guarantors (the "<u>Existing Subsidiary Guarantors</u>") under the indenture referred to below, and The Bank of New York Mellon Trust Company, N.A., a banking association organized under the laws of the United States of America, as trustee (in such capacity, "<u>Trustee</u>") and as notes collateral agent (in such capacity, "<u>Notes Collateral Agent</u>") under the indenture referred to below.

W I T N E S S E T H :

WHEREAS the Company and the Existing Subsidiary Guarantors have heretofore executed and delivered to the Trustee an Indenture (the "<u>Indenture</u>") dated as of July 27, 2020, as amended on August 27, 2021 and March 31, 2022, providing for the issuance of an unlimited aggregate principal amount of 8.000% Senior Secured Notes due 2026 (the "<u>Securities</u>");

WHEREAS Section 4.09 of the Indenture provides that under certain circumstances the Company is required to cause the New Subsidiary Guarantor to execute and deliver to the Trustee a supplemental indenture pursuant to which the New Subsidiary Guarantor shall unconditionally guarantee all the Company's obligations under the Securities pursuant to a Subsidiary Guarantee on the terms and conditions set forth herein; and

WHEREAS pursuant to Section 9.01 of the Indenture, the Trustee, the Company and the Existing Subsidiary Guarantors are authorized to execute and deliver this Supplemental Indenture.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the New Subsidiary Guarantor, the Company, the Existing Subsidiary Guarantors and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Securities as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.<u>Agreement to Guarantee.</u> The New Subsidiary Guarantor hereby agrees, jointly and severally, on a senior secured basis, with all other Subsidiary Guarantors, to unconditionally guarantee the Company's obligations under the Securities and the Indenture on the terms and subject to the conditions set forth in Article X of the Indenture and to be bound by all other applicable provisions of the Indenture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.<u>Ratification of Indenture; Supplemental Indentures Part of Indenture.</u> Except as expressly amended hereby, the Indenture is in all respects ratified and confirmed and all the terms, conditions and provisions thereof shall remain in full force and effect. This Supplemental Indenture shall form a part of the Indenture for all purposes, and every holder of Securities heretofore or hereafter authenticated and delivered shall be bound hereby.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.<u>Governing Law.</u> **THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK BUT WITHOUT REFERENCE TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.<u>Trustee Makes No Representation.</u> The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture and shall not be responsible for the recitals contained herein, all which recitals are made solely by the other parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.<u>Counterparts.</u> The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of them together represent the same agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.<u>Effect of Headings.</u> The Section headings herein are for convenience only and shall not effect the construction thereof.

[*Remainder of Page Intentionally Left Blank*]

------

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed as of the date first above written.

JUNIPER RX, LLC

By: */s/* <u>Lisa Winnick</u> <br>Name:Lisa Winnick<br>Title:Vice President and Assistant Secretary

RITE AID CORPORATION, on behalf of itself and the existing subsidiary guarantors

By: */s/* <u>Paul Gilbert</u> <br>Name:Paul Gilbert<br>Title:Executive Vice President, Chief Legal

Officer and Secretary

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as trustee

By: */s/* <u>Shannon Matthews</u> <br>Name:Shannon Matthews<br>Title:Vice President

THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., as notes collateral agent,

By: */s/* <u>Shannon Matthews</u> <br>Name:Shannon Matthews<br>Title:Vice President

[Signature Page to Supplemental Indenture for the 2026 Notes]

------

## Ex-22

**Exhibit 22**

**List of Guarantor Subsidiaries**

The Guaranteed Notes are jointly and severally guaranteed on a full and unconditional basis by Rite Aid Corporation (incorporated in Delaware) and the following 100% owned subsidiaries of Rite Aid Corporation as of November 26, 2022:

---

| | |
|:---|:---|
| **Entity** | **Jurisdiction of Incorporation or Organization** |
| Harco, Inc. | Alabama |
| K & B Alabama Corporation | Alabama |
| Rite Aid Lease Management Company (a California corporation) | California |
| Thrifty Corporation (a California corporation) | California |
| Thrifty PayLess, Inc. (a California corporation) | California |
| Rite Aid of Connecticut, Inc. | Connecticut |
| 1515 West State Street Boise, Idaho, LLC (a Delaware limited liability company) | Delaware |
| Ascend Health Technology, LLC (a Delaware limited liability company) | Delaware |
| Design Rx Holdings, LLC (a Delaware limited liability company) | Delaware |
| Eckerd Corporation (a Delaware corporation) | Delaware |
| Elixir Puerto Rico, Inc. (a Delaware corporation) | Delaware |
| Genovese Drug Stores, Inc. (a Delaware corporation) | Delaware |
| Health Dialog Services Corporation (a Delaware corporation) | Delaware |
| Hunter Lane, LLC (a Delaware limited liability company) | Delaware |
| JCG (PJC) USA, LLC (a Delaware limited liability company) | Delaware |
| JCG Holdings (USA), Inc. (a Delaware corporation) | Delaware |
| Juniper Rx, LLC | Delaware |
| K & B, Incorporated (a Delaware corporation)  | Delaware |
| Maxi Drug North, Inc. (a Delaware corporation) | Delaware |
| Maxi Drug South, L.P. (a Delaware limited partnership) | Delaware |
| Maxi Drug, Inc. (a Delaware corporation) | Delaware |
| Munson & Andrews, LLC (a Delaware limited liability company) | Delaware |
| Name Rite, LLC (a Delaware limited liability company) | Delaware |
| P.J.C. Distribution, Inc. (a Delaware corporation) | Delaware |
| P.J.C. Realty Co., Inc. (a Delaware corporation) | Delaware |
| PJC Lease Holdings, Inc. (a Delaware corporation) | Delaware |
| PJC Manchester Realty LLC (a Delaware limited liability company) | Delaware |
| PJC Peterborough Realty LLC | Delaware |
| PJC Revere Realty LLC (a Delaware limited liability company) | Delaware |
| PJC Special Realty Holdings, Inc. (a Delaware corporation) | Delaware |
| RediClinic Associates, Inc. (a Delaware corporation) | Delaware |
| RediClinic LLC (a Delaware limited liability company) | Delaware |

---

------

---

| | |
|:---|:---|
| **Entity** | **Jurisdiction of Incorporation or Organization** |
| RediClinic of PA, LLC (a Delaware limited liability company) | Delaware |
| Rite Aid Corporation (PARENT) | Delaware |
| Rite Aid Drug Palace, Inc. (a Delaware corporation) | Delaware |
| Rite Aid Hdqtrs. Corp. (a Delaware corporation) | Delaware |
| Rite Aid Hdqtrs. Funding, Inc. (a Delaware corporation) | Delaware |
| Rite Aid of Delaware, Inc. (a Delaware corporation) | Delaware |
| Rite Aid Online Store Inc. (a Delaware corporation) | Delaware |
| Rite Aid Payroll Management Inc. (a Delaware corporation) | Delaware |
| Rite Aid Realty Corp. (a Delaware corporation) | Delaware |
| Rite Aid Specialty Pharmacy LLC (a Delaware limited liability company) | Delaware |
| Rite Aid Transport, Inc. (a Delaware corporation) | Delaware |
| Rite Investments Corp. (a Delaware corporation) | Delaware |
| Rite Investments Corp., LLC (a Delaware limited liability company) | Delaware |
| Rx Choice, Inc. (a Delaware corporation) | Delaware |
| The Jean Coutu Group (PJC) USA, Inc. (a Delaware corporation) | Delaware |
| Thrift Drug Inc. (a Delaware corporation) | Delaware |
| Advance Benefits, LLC | Florida |
| Elixir Savings, LLC | Florida |
| First Florida Insurers of Tampa, LLC | Florida |
| Rite Aid of Georgia, Inc. | Georgia |
| Rite Aid of Indiana, Inc. | Indiana |
| Rite Aid of Kentucky, Inc. | Kentucky |
| K & B Louisiana Corporation | Louisiana |
| K & B Services, Incorporated | Louisiana |
| Rite Aid of Maine, Inc. | Maine |
| GDF, Inc. | Maryland |
| READ'S, Inc. | Maryland |
| Rite Aid of Maryland, Inc. | Maryland |
| PJC of Massachusetts, Inc. (a Massachusetts corporation) | Massachusetts |
| PJC Realty MA, Inc. (a Massachusetts corporation) | Massachusetts |
| 1740 Associates, LLC | Michigan |
| Apex Drug Stores, Inc. | Michigan |
| PDS-1 Michigan, Inc. | Michigan |
| Perry Drug Stores, Inc. | Michigan |
| RDS Detroit, Inc. | Michigan |
| Rite Aid of Michigan, Inc. | Michigan |
| Laker Software, LLC | Minnesota |
| K & B Mississippi Corporation | Mississippi |
| Elixir Rx Solutions, LLC | Missouri |
| Elixir Rx Solutions of Nevada | Nevada |
| Rite Aid of New Hampshire, Inc. | New Hampshire |
| Lakehurst and Broadway Corporation | New Jersey |
| Rite Aid of New Jersey, Inc. | New Jersey |

---

------

---

| | |
|:---|:---|
| **Entity** | **Jurisdiction of Incorporation or Organization** |
| Rite Aid of New York, Inc. (a New York corporation) | New York |
| Rite Aid Rome Distribution Center, Inc. (a New York corporation) | New York |
| EDC Drug Stores, Inc. | North Carolina |
| Rite Aid of North Carolina, Inc. | North Carolina |
| 4042 Warrensville Center Road - Warrensville Ohio, Inc. | Ohio |
| 5600 Superior Properties, Inc. | Ohio |
| Broadview and Wallings-Broadview Heights Ohio, Inc. | Ohio |
| Elixir Rx Solutions, LLC | Ohio |
| Gettysburg and Hoover - Dayton, Ohio, LLC | Ohio |
| Elixir Pharmacy, LLC | Ohio |
| Rite Aid of Ohio, Inc. | Ohio |
| Elixir Rx Options, LLC | Ohio |
| The Lane Drug Company | Ohio |
| Tonic Procurement, LLC | Ohio |
| Rite Aid of Pennsylvania, LLC (Formerly Rite Aid of Pennsylvania, Inc.) | Pennsylvania |
| PJC of Rhode Island, Inc. | Rhode Island |
| Rite Aid of South Carolina, Inc. | South Carolina |
| K & B Tennessee Corporation | Tennessee |
| Rite Aid of Tennessee, Inc. | Tennessee |
| K & B Texas Corporation (a Texas corporation) | Texas |
| RCMH, LLC (a Texas limited liability company) | Texas |
| Rx Initiatives, L.L.C.  | Utah |
| Maxi Green, Inc. | Vermont |
| PJC of Vermont, Inc. | Vermont |
| Rite Aid of Vermont, Inc. | Vermont |
| Rite Aid of Virginia, Inc. | Virginia |
| Rite Aid of Washington, D.C., Inc. | Wash. D.C. |
| 5277 Associates, Inc. | Washington |
| The Bartell Drug Company | Washington |
| Rite Aid of West Virginia, Inc. | West Virginia |
| Design Rx, LLC | Wyoming |
| Design Rxclusives, LLC | Wyoming |

---

------

## Exhibit 31.1

**Exhibit 31.1**

**Certification of Chief Executive Officer**

I, Heyward Donigan, President and Chief Executive Officer, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the "Registrant");

2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 4, 2023 |  |  |
|  | By: | /s/ HEYWARD DONIGAN |
|  |  | Heyward Donigan |
|  |  | *President and Chief Executive Officer* |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**Certification of Chief Financial Officer**

I, Matthew C. Schroeder, Executive Vice President and Chief Financial Officer, certify that:

1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this quarterly report on Form 10-Q of Rite Aid Corporation (the "Registrant");

2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 4, 2023 |  |  |
|  | By: | /s/ MATTHEW C. SCHROEDER |
|  |  | Matthew C. Schroeder |
|  |  | *Executive Vice President and Chief Financial Officer* |

---

------

## Ex-32

**Exhibit 32**

**Certification of CEO and CFO Pursuant to**

**18 U.S.C. Section 1350, as Adopted Pursuant to**

**Section 906 of the Sarbanes-Oxley Act of 2002**

In connection with the Quarterly Report on Form 10-Q of Rite Aid Corporation (the "Company") for the quarterly period ended November 26, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Heyward Donigan, as President and Chief Executive Officer of the Company, and Matthew C. Schroeder, as Executive Vice President and Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of her or his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| /s/ HEYWARD DONIGAN | /s/ HEYWARD DONIGAN |
| Name: | Heyward Donigan |
| Title: | *President and Chief Executive Officer* |
| Date: | January 4, 2023 |
| /s/ MATTHEW C. SCHROEDER | /s/ MATTHEW C. SCHROEDER |
| Name: | Matthew C. Schroeder |
| Title: | *Executive Vice President and Chief Financial Officer* |
| Date: | January 4, 2023 |

---

------